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A B S T R A C T
Background
Cystic fibrosis is caused by a defective gene encoding a protein called the cystic fibrosis transmembrane conductance regulator (CFTR),
and is characterised by chronic lung infection resulting in inflammation and progressive lung damage that results in a reduced life
expectancy.
Objectives
Todetermine whether topical CFTRgene replacement therapy to the lungs in people with cystic fibrosis is associatedwith improvements
in clinical outcomes, and to assess any adverse effects.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from compre-
hensive electronic database searches, handsearching relevant journals and abstract books of conference proceedings.
Date of most recent search: 05 May 2016.
An additional search of the National Institutes for Health (NIH) Genetic Modification Clinical Research Information System
(GeMCRIS) was also performed for the years 1992 to 2015.
Date of most recent search: 20 April 2016.
Selection criteria
Randomised controlled studies comparing topical CFTR gene delivery to the lung, using either viral or non-viral delivery systems, with
placebo or an alternative delivery system in people with confirmed cystic fibrosis.
Data collection and analysis
The authors independently extracted data and assessed study quality. Authors of included studies were contacted and asked for any
available additional data. Meta-analysis was limited due to differing study designs.
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Main results
Four randomised controlled studies met the inclusion criteria for this review, involving a total of 302 participants lasting from 29 days
to 13 months; 14 studies were excluded. The included studies differed in terms of CFTR gene replacement agent and study design,
which limited the meta-analysis. One study only enrolled adult males, the remaining studies included both males and females aged 12
years and over.
Risk of bias in the studies was moderate. Random sequence generation and allocation concealment was only described in the more
recent study; the remaining three studies were judged to have an unclear risk of bias. All four studies documented double-blinding to
the intervention, but there is some uncertainty with regards to participant blinding in one study. Some outcome data were missing
from all four studies.
There were no differences in either the number of respiratory exacerbations or the number of participants with an exacerbation between
replacement therapy or placebo groups at any time point. Meta-analysis of most respiratory function tests showed no difference between
treatment and placebo groups, but the smallest study (n = 16) reported forced vital capacity (litres) increased more in the placebo group
at up to 24 hours. A further study reported a significant improvement in forced expiratory volume at one second (litres) at 30 days after
participants had received their first dose of favouring the gene therapy agent, but this finding was not confirmed when combined with
at second study in the meta-analysis. The more recent study (n = 140) demonstrated a small improvement in forced vital capacity (per
cent predicted) at two and three months and again at 11 and 12 months for participants receiving CFTR gene replacement therapy
compared to those receiving placebo. The same study reported a significant difference in the relative change in forced expiratory volume
at one second (per cent predicted) at two months, three months and 12 months.
One small study reported significant concerns with “influenza-like” symptoms in participants treated with CFTR gene replacement
therapy; this was not reported on repeated use of the same agent in a larger recent study.
There was no other evidence of positive impact on outcomes, in particular improved quality of life or reduced treatment burden.
Two studies measured ion transport in the lower airways; one (n = 16) demonstrated significant changes toward normal values in the
participants who received gene transfer agents (P < 0.0001), mean difference 6.86 (95% confidence interval 3.77 to 9.95). The second
study (n = 140) also reported significant changes toward normal values (P = 0.032); however, aggregate data were not available for
analysis. In the most recent study, there was also evidence of increased salt transport in cells obtained by brushing the lower airway.
These outcomes, whilst important, are not of direct clinical relevance.
Authors’ conclusions
One study of liposome-based CFTR gene transfer therapy demonstrated some improvements in respiratory function in people with
CF, but this limited evidence of efficacy does not support this treatment as a routine therapy at present. There was no evidence of
efficacy for viral-mediated gene delivery.
Future studies need to investigate clinically important outcome measures.
P L A I N L A N G U A G E S U M M A R Y
Replacing the defective gene is a potential treatment for progressive lung disease in people with cystic fibrosis
Review question
We reviewed the evidence about the effect of delivering the correct copy of the cystic fibrosis transmembrane conductance regulator
(CFTR) gene directly to the lungs of people with cystic fibrosis in order to treat progressive lung disease.
Background
In cystic fibrosis the gene encoding a protein called the cystic fibrosis transmembrane conductance regulator (CFTR) is faulty. People
with cystic fibrosis suffer from progressive lung infection and damage which reduces life expectancy. Agents which can deliver a correct
copy of the faulty CFTR gene to cells in the lungs may be an effective treatment.
Search date
The evidence is current to: 20 April 2016.
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Study characteristics
We found four studies with 302 people to include in this review. The studies lasted from 29 days to 13 months. Three of these studies
included both men and women aged 12 years and over and one study only included adult men. The studies compare gene therapy to a
dummy treatment (placebo) both of which are inhaled as a mist into the lungs. The studies were of different designs and used different
agents. This meant we could not combine their results.
Key results
Three of the studies, including the largest and most recent study, showed an improvement in some measures of lung function in people
with CF given gene therapy. We did not find that any more clinically relevant outcomes such as quality of life, treatment burden or
flare-up of lung disease had improved with treatment. In one study “influenza-like” symptoms were more common in people who
received CFTR gene transfer agents but this was not reported when the agent was used repeatedly in a larger study. In those people
who took the gene transfer agents, molecules and salt in their lower airways moved more like they do in healthy people.
The limited evidence of benefit does not support this as a routine therapy at present. We recommend that future studies are designed
and reported clearly so that their results can be incorporated into a systematic review.
Quality of the evidence
Themost recent study provided detailed information on how the people were put into different treatment groups completely at random,
and so we are satisfied that those taking part in the study had an equal chance of being in either group (CFTR gene transfer agent or
placebo) and that no one could work out which group the next person would be put into. The other studies reported that people were
put into groups at random but did not specify how, so we cannot be sure that there was an equal chance of them being in either group.
We believe that the clinicians running all the studies did not know which treatment the people taking part were receiving and that in
three of the studies those taking part did not know either, but we could not be sure whether the people taking part in the latest study
knew which treatment they were receiving and what effect this knowledge might have on results. Unfortunately, the studies did not
report all their results clearly; sometimes results were not reported in a way that we could use for the review and sometimes they were
not reported at all. This reduced the certainty with which we judged the overall results.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the commonest life-shortening disease in
Caucasians and is caused by a single gene defect. It has a preva-
lence of approximately 1 in 2000 at birth (Bobadilla 2002). The
affected gene is responsible for making a protein called the cys-
tic fibrosis transmembrane conductance regulator (CFTR). There
are many abnormalities or alterations of the CFTR gene that can
affect the production and function of CFTR (Rowntree 2003).
Normally,CFTR has an important role in co-ordinating salt trans-
port across cell membranes. This role is particularly important in
the lungs where an abnormality of CFTR results in dehydration
of the surface liquid that lines the airways (Matsui 1998). Conse-
quently the airway is not able to remove bacteria and chronic air-
way infection results in an intense local inflammation and mucus
secretion (Boucher 2004). Subsequently a cycle of increasing lung
inflammation and lung damage progressively reduces lung func-
tion, leading eventually to premature death (often in the third or
fourth decade of life) from respiratory failure (FitzSimmons 1993;
Frederiksen 1996).
Description of the intervention
These disease processes could be prevented by inserting a correct
copy of the CFTR gene into the cells of people with CF, a process
termed CFTR gene transfer therapy (Griesenbach 2004).
How the intervention might work
There are three main reasons why CFTR gene transfer therapy has
been proposed for CF lung disease:
1. the CFTR gene has been identified and characterised and it
is possible to manufacture artificial CFTR genes (Riordan 1989);
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2. CF is a progressive condition with a potential window for
early treatment when the lungs are relatively unaffected
(Ranganathan 2004);
3. delivery of gene therapy reagents to the lungs may be
possible by aerosolisation or other methods of topical application
(Lee 2005).
Early laboratory studies demonstrated the successful transfer of
the CFTR gene to cells and animal airways using a variety of dif-
ferent gene delivery methods (Southern 1996). Essentially, deliv-
ery agents have been described as viral (where the CFTR gene is
incorporated into a replication incompetent virus) and non-viral
(most commonly positively-charged liposomes which whenmixed
with DNA increases uptake into cells) (Lee 2005). Human studies
using viral vectors suggest that topical delivery to nasal airway cells
results in uptake of the CFTR gene and expression of the gene
by the airway cells (Knowles 1995; Zabner 1996). These studies
demonstrate some correction of abnormal salt transport; however,
repeat dosing results in inflammation (immune-mediated) and no
detectable gene transfer (Harvey 1999; Zabner 1996). Repeated
dosing of non-viral gene delivery agents does not result in such
marked immune-mediated responses; however, steady-state levels
of gene expression and functional changes have been less impres-
sive than those achievable acutely with viral vectors (Hyde 2000).
Much effort is being directed towards developing gene transfer
agents and strategies with both improved gene uptake and expres-
sion, and reduced immunogenicity (Ferrari 2002; Griesenbach
2004; Lee 2005).
Why it is important to do this review
This review is an updated version of previous Cochrane Reviews
(Lee 2007; Lee 2012). It focuses on treatment of CF lung disease
as this is the major cause of morbidity and mortality in people
with CF, however abnormal CFTR function affects other parts of
the body, some of which may be amenable to other forms of gene
transfer therapy but will not be the subject of this review.
O B J E C T I V E S
To investigate whether topical CFTR gene replacement therapy
to the lungs of people with CF is associated with improvements
in clinical outcomes (respiratory function and quality of life) and
assess existing or predicted adverse effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), published or unpublished.
Controlled clinical trials (CCTs), including quasi-randomised
controlled trials, will be included in future updates if available and
only if there is sufficient evidence that control and intervention
groups were similar at baseline.
Types of participants
Children and adults with CF confirmed by the presence of two
disease-causing mutations, or by a combination of positive sweat
test and recognised clinical features of CF.
Types of interventions
Topical CFTR gene delivery to the lung, using either viral or non-
viral vector systems, compared to placebo or an alternative vector
system.
Types of outcome measures
Primary outcomes
1. Respiratory exacerbations (assessed by need for additional
oral or intravenous antibiotics)*
i) oral antibiotics (days or episodes)
ii) intravenous antibiotics (days or episodes)
2. Lung function testing (absolute values or percent predicted
for age, sex and height)
i) forced expiratory volume at one second (FEV1)
ii) forced vital capacity (FVC)
iii) relative change in FEV1 or FVC
iv) other relevant lung function tests (for example, infant
lung function tests and lung clearance index)
3. Survival (either as a binary outcome or time to event)*
Secondary outcomes
1. Number of days as a hospital inpatient (or number of
inpatient episodes)*
2. Need for extra treatment*
i) physiotherapy (duration or episodes)
3. Adverse events*
i) mild (e.g. sore throat, hoarse voice, dry mouth)
ii) moderate (e.g. wheeze, cough, fever, local allergic
reaction)
iii) severe (e.g. coughing up blood (haemoptysis),
collapsed lung (pneumothorax), chest infection, systemic allergic
reactions)
4. Quality of life (as measured by a validated and appropriate
method)*
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5. School or work attendance*
6. Nutritional parameters (including z scores or centiles)
i) weight
ii) body mass index (BMI)
iii) height
7. Acquisition of newly cultured respiratory pathogens
i) Pseudomonas aeruginosa
ii) Staphylococcus aureus
iii) Haemophilus influenzae
8. Sputum rheology (stickiness, as measured by a validated
method)
9. Mucociliary clearance of the airway (as measured by a
validated method)
10. Airway potential difference measurements (measuring salt
transport)
i) Baseline potential difference
ii) Response to perfusion with amiloride
iii) Response to perfusion with a zero chloride solution
11. Measures of gene expression
i) quantitative reverse transcription polymerase chain
reaction (rtPCR) to measure vector-specific CFTR messenger
ribonucleic acid (mRNA) production
ii) any other method of measuring gene expression
12. Measures of CFTR protein expression
13. Radiological measures of lung disease
i) validated chest radiograph scores
ii) validated computerised tomogram (CT) score
*indicates outcomes that have a direct influence on the person
with CF (and therefore are more pragmatic measures of efficacy).
Search methods for identification of studies
Electronic searches
Relevant studies were identified from the Group’s Cystic Fibrosis
Trials Register using the search term: topical (aerosolized) CFTR
gene replacement for the lungs.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
quarterly searches of MEDLINE, a search of Embase to 1995
and the prospective handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work is
identified by searching the abstract books of three major cystic
fibrosis conferences: the International Cystic Fibrosis Conference;
the European Cystic Fibrosis Conference and theNorth American
Cystic Fibrosis Conference. For full details of all searching activi-
ties for the register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group Module.
Date of latest search of the Group’s Trials Register: 05 May 2016.
An additional search of the National Institutes for Health (NIH)
Genetic Modification Clinical Research
Information System (GeMCRIS) was also performed for the years
1992 to 2016 (Appendix 1).
Date of latest search: 20 April 2016.
Searching other resources
Investigators who work in the field and previous authors were also
contacted for unpublished or additional data.
Data collection and analysis
Selection of studies
For the initial review and earlier updates, two authors (TWRL and
KWS) independently selected the studies to be included in the
review. From 2015 two co-authors (JP-D and LP) selected studies.
There was agreement between the authors on the suitability of
studies for inclusion in the review.
Data extraction and management
For the initial review and earlier updates, two authors (TWRL and
KWS) independently extracted data for the review. From 2015
two co-authors (JP-D and LP) extracted data from the included
studies. The authors used a standardised form to extract data from
studies eligible for inclusion in the review. If the publications pro-
vided standard errors (SEs), the authors converted these to stan-
dard deviations (SDs). The authors undertook meta-analysis on
data from all included studies.
As the effect of gene transfer therapy may be cumulative, we anal-
ysed studies with different durations of intervention separately. For
example, we planned to combine studies of less than one month
duration, studies between one and two months duration, three
and four months duration and five and six months duration. We
planned to combine studies longer than six months duration on
a three-monthly basis. Regarding studies of less than one month
duration, in a post hoc change to protocol, we did not consider it
appropriate to combine six-hour data with Day 30 data, as data
obtained within 24 hours of administration are related to moni-
toring of adverse effects rather than efficacy.
We report when measurements were taken by the primary investi-
gators during the study, what measurements were reported within
the published paper and what data we are reporting in the review
(see Additional Tables (Table 1; Table 2)).
Assessment of risk of bias in included studies
In order to establish a risk of bias, two authors independently
assessed the studies to be included in the review.Originally, TWRL
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and KWS assessed the methodological quality of each study based
on a method described by Jüni and colleagues (Jüni 2001). The
authors assessed the following:
• a description of the degree of blinding;
• inclusion of all participants in an intention-to-treat analysis,
regardless of whether they completed the treatment schedule or
not;
• whether there is a clear description of generation of
allocation sequence, for example with a random numbers table;
• whether concealment of allocation sequence is described,
for example if neither investigators nor participants can foresee
assignment to either treatment or control group.
There was agreement between the authors on the quality of studies
for inclusion in the review.
For more recent updates of the review, all authors assessed the risk
of bias of the included studies using the risk of bias tool developed
by Cochrane (Higgins 2011).
Measures of treatment effect
For binary outcome measures, the authors calculated a pooled es-
timate of the treatment effect for each outcome across studies us-
ing the risk ratio (RR). For continuous outcomes, they recorded
either mean relative change from baseline for each group or mean
post-treatment or intervention values and SD. They calculated a
pooled estimate of treatment effect by calculating the mean dif-
ference (MD) with 95% confidence intervals (CIs). Authors con-
verted any SEs to SDs. To calculate the SD for change from base-
line in bronchial potential difference from the most recent Alton
study, authors assumed the correlation coefficient to be 0.9 and
performed sensitivity analysis at a range of values (Alton 2015).
For studies reporting continuous outcomes atmultiple time points
there are currently no methods to analyse aggregate longitudinal
data if individual patient data are not available. Therefore in this
review the authors have carried out analysis at each individual
time point reported and assumed zero correlation between results.
For any outcomes producing time-to-event data (e.g. survival) or
count data (e.g. number of days), they analysed the data using the
most appropriate method.
Unit of analysis issues
The review authors planned to consider studies with a cross-over
design for inclusion; however, they have concerns about the po-
tential for ’hangover effects’ following too brief a washout period
(Southern 2003). This is particularly pertinent for gene transfer
therapy agentswhichmay alter the natural history of theCFairway
disease. The review authors would have analysed any data from
cross-over studies that were eligible for inclusion using a method
described by Elbourne (Elbourne 2002). Elbourne says that this
approach will produce conservative results, as it does not take into
account within-patient correlation. Also, each participant will ap-
pear in both the treatment and control group, so the two groups
will not be independent. If cross-over studies are included in fu-
ture updates of this review we will undertake a sensitivity analysis
to determine the effect of these studies on the overall result.
Dealing with missing data
In order to allow an intention-to-treat (ITT) analysis, the review
authors sought data on the number of participants with each out-
come event, by allocated treated group, irrespective of compliance
and whether or not the individual was later thought to be ineli-
gible or otherwise excluded from treatment or follow up. The re-
view authors contacted the investigators of one study and obtained
some additional data for inclusion in the review (Alton 2015).
Assessment of heterogeneity
Since the authors only included four studies and were not able to
combine data for many outcomes, they did not assess heterogene-
ity. If they are able to include more studies in future updates of
the review, they will assess heterogeneity through a visual exam-
ination of the combined data presented in the forest plots, and
by considering the I2 statistic (Higgins 2003) together with Chi
2 values and their CIs (Deeks 2011). This reflects the likelihood
that variation of results across trials are due to heterogeneity rather
than chance, and the authors will interpret this statistic using the
following simple classification:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
In order to identify selective outcome reporting, where possible,
the authors compared outcomes defined in the protocol with those
reported in the full publication. The authors requested the pro-
tocol for the study from the primary investigators, correspond-
ing author(s), or relevant pharmaceutical company and recorded
whether the protocol was available or not. They also compared
outcomes listed in the ’Methods’ section of the final paper with
those presented in the ’Results’ section. For negative findings that
were reported either only partially, or not at all, the authors con-
tacted primary investigators for these data.
In future updates, should sufficient studies become available, the
authors will attempt to assess whether this review is subject to pub-
lication bias by using a funnel plot (which graphically illustrates
variability between studies and should not demonstrate a system-
atic difference). If the authors detect asymmetry, they will explore
causes other than publication bias.
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Data synthesis
The authors have analysed the data included in the review using
a fixed-effect model. If in future they identify a moderate or high
degree of heterogeneity, they plan to analyse the data using a ran-
dom-effects model.
Subgroup analysis and investigation of heterogeneity
If the authors had identified any heterogeneity, they would have
investigated this using subgroup analysis of potential effect mod-
ifiers. The major potential effect modifier is age, other effects in-
clude sex and treatment centre.
Sensitivity analysis
If cross-over studies are included in future updates of this review
the authors will undertake a sensitivity analysis to determine the
effect of these studies on the overall result.
R E S U L T S
Description of studies
Results of the search
The searches identified 18 studies in the searches, but only four
were eligible for inclusion in the review; the remaining 14 studies
were excluded from the review.
Included studies
Four of the 18 studies identified in the searches were eligible for
inclusion in the review (Alton 1999; Alton 2015; Moss 2004;
Moss 2007).
Study Design
All four studies were RCTs of parallel design comparing CFTR
gene replacement delivered to the lungs of people with CF to
placebo (Alton 1999; Alton 2015; Moss 2004; Moss 2007). One
study was single centre (Alton 1999) and the remaining studies
were multicentre; one was conducted at two sites recruiting from
18 centres (Alton 2015), one recruited from eight centres (Moss
2004) and the remaining one from 12 centres (Moss 2007). The
Moss studies were conducted in the USA and the Alton studies
were conducted in the UK (Alton 1999; Alton 2015; Moss 2004;
Moss 2007).
The largest study randomised 140 participants into treatment and
placebo groups and 136 participants received at least one dose of
the study drug (Alton 2015). The second largest study recruited
109 participants and 102 received at least one dose of the study
drug (Moss 2007). Moss 2004 randomised 42 participants and
37 received at least one dose of study drug (Moss 2004). The
smallest study randomised 16 participants and all received at least
one study dose (Alton 1999).
Three studies reported power calculations (Alton 2015; Moss
2004; Moss 2007). Alton calculated adequate power to test dif-
ferences between treatment groups for the primary protocol end-
point, relative change in % predicted FEV1 (Alton 2015). Both
Moss studies reported calculating adequate power to test differ-
ences between treatment groups with respect to the primary and
secondary protocol end points (Moss 2004; Moss 2007).
The longest follow up of participants was 13months (Alton 2015)
and shortest was 29 days (Alton 1999). In Moss 2004, follow up
was 150 days (Moss 2004), whereas Moss 2007 had outcome-
dependent follow up, with 90 days for lung function and 210 days
for adverse event monitoring (Moss 2007).
Participants
In total, all four studies randomised 302 participants with CF
(Alton 1999; Alton 2015; Moss 2004; Moss 2007). One study
recruited only male participants due to regulatory restrictions (
Alton 1999). The remaining three studies recruited both males
and females with an approximately even gender split in each group,
except for the treatment group in Moss 2004 where there were
more than double the number of females to males (14 females, six
males) (Alton 2015; Moss 2004; Moss 2007).
With regards to age, one study specified that all participants were
adults with a mean age of 26.9 years (Alton 1999). The remaining
three studies recruited participants of at least 12 years of age; the
mean age of participants was 24.7 years (Alton 2015), 23.7 years
(Moss 2004) and 22.6 years (Moss 2007). A breakdown of the
mean ages of participant by treatment group is available in the
tables (Characteristics of included studies).
All studies reported the genotypes of participants. Alton 1999 re-
ported that 12 out of 16 participants were homozygous 1F508,
but did not report the numbers for each mutation separately by
treatment group (Alton 1999). Alton 2015 stated that the ho-
mozygous1F508 genotype was the commonest, with 48% in the
placebo group and 50% in the treatment group (Alton 2015).
In Moss 2004 there were significantly more 1F508 homozygous
participants (77%) in the placebo group than in the CFTR gene
replacement group (25%) (P = 0.01) (Moss 2004). Moss 2007
recruited slightly more1F508 homozygous participants - 53% in
each group (Moss 2007).
With regard to other participant characteristics, all studies stated a
minimum FEV1 % predicted score; at least 70% (Alton 1999), at
least 50% (Alton 2015) and at least 60% (Moss 2004;Moss 2007).
Alton 1999 reported that there were no significant differences
between groups in terms of BMI, or chest x-ray score (Alton
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1999) and Alton 2015 reported no significant difference in BMI
and centre distribution number (Alton 2015). Both Moss studies
reported that treatment and placebo groups were similar in terms
of demographics and clinical characteristics (Moss 2004; Moss
2007).
Interventions
All four studies compared an active treatment to a placebo (Alton
1999; Alton 2015; Moss 2004; Moss 2007). The Alton studies
delivered the CFTR gene as plasmid DNA complexed with lipo-
some (GL-67/DOPE/DMPE-PEG5000). In the treatment group
for the 1999 study, Alton nebulised 16 ml from a 20 ml solution
containing 42.2 mg of plasmid DNA (pCF-1-CFTR) once to the
lungs whilst the placebo group received liposome alone (Alton
1999). In Alton 2015, the treatment group received 5 ml nebu-
lised solution containing 13.3 mg of plasmid DNA, pGM169, at
28-day intervals (plus or minus five days) over 12 months, whilst
the placebo group received 5 ml of nebulised 0.9% saline (Alton
2015).
Both Moss studies used the adeno-associated virus serotype 2
(AAV-2) vector tgAAVCF to deliver the CFTR gene (Moss 2004;
Moss 2007). In Moss 2004, 1x1013 particles tgAAVCF or match-
ing placebo were nebulised to the lungs on three occasions 30 days
apart (Moss 2004). Moss 2007 used a similar design, but used two
instead of three doses, but still 30 days apart (Moss 2007).
Outcomes
Adverse events and lung function were the only outcomes mea-
sured by all four trials (Alton 1999; Alton 2015;Moss 2004;Moss
2007). However, lung function was reported in a number of ways:
three studies reported on the change from baseline in FEV1 (L)
(Alton 1999; Moss 2004; Moss 2007); two studies reported the
change from baseline in FEV1 (% predicted) (Moss 2004; Moss
2007); three studies reported on the change from baseline in FVC
(L) (Alton 1999; Moss 2004;Moss 2007); and one study reported
on both the change from baseline in FVC (% predicted) and
the relative change in FEV1 (% predicted) (Alton 2015). Three
studies reported on respiratory exacerbations (Alton 2015; Moss
2004;Moss 2007). Both Alton studies andMoss 2004 reported on
changes in measures of CFTR protein function (gene expression,
CFTR protein expression and airway potential difference) (Alton
1999, Alton 2015; Moss 2004). Two studies reported on comput-
erised tomography (Alton 2015; Moss 2004). Alton 2015 addi-
tionally reported on quality of life (QoL) assessment, lung clear-
ance index, and changes in sputum microbiology (Alton 2015).
Moss 2004 reported on inpatient episodes and the acquisition of
new pathogens (Moss 2004).
Excluded studies
We excluded 14 studies from the results of the search (see
Characteristics of excluded studies). Eight of the excluded studies
were not RCTs (Davies 2011; Flotte 1996; Harvey 1999; Joseph
2001; Noone 2000; Zabner 1996; Zabner 1997; Zuckerman
1999). The remaining six studies were excluded since the therapy
was not applied directly to the lungs; four studies applied treat-
ment to the nose (Gill 1997; Hyde 2000; Knowles 1995; Porteous
1997) and two studies applied treatment to the sinuses (Wagner
1999; Wagner 2002).
Risk of bias in included studies
Allocation
All four included studies were described as randomised (Alton
1999; Alton 2015;Moss 2004;Moss 2007), but only one gave any
specific details of the methodology for randomisation and con-
cealment of allocation (Alton 2015). We therefore judged Alton
2015 to have a low risk of bias regarding the generation of allo-
cation sequence and the concealment of allocation sequence, and
the remaining three studies to have an unclear risk of bias (Alton
1999; Alton 2015; Moss 2004; Moss 2007).
Blinding
In all four studies there was double blinding to the intervention
(Alton 1999; Alton 2015; Moss 2004; Moss 2007); however, only
the Alton studies explicitly stated that both participants and out-
come assessorswere blinded (Alton 1999; Alton2015). Alton2015
used 0.9% saline as the placebo; and although the investigators
stated that nebulisers were sealed we cannot be sure that partici-
pants would have been adequately blinded to the study drug due
to potential differences in taste and consistency (Alton 2015). We
therefore deemed all four studies to have a low risk of bias with
regards to blinding of personnel (Alton 1999; Alton 2015; Moss
2004;Moss 2007). However, we judged three studies to have a low
risk of bias with regards to blinding of participants (Alton 1999;
Moss 2004; Moss 2007) and one study to have an unclear risk of
bias (Alton 2015).
Incomplete outcome data
Alton 1999 assessed all randomised participants on an ITT basis,
although data are incomplete for four of the reported endpoints
(nasal histology, viability of lipid complex, chloride efflux and
bacterial adherence) (Alton 1999). For these endpoints there is
thus a potential risk of bias.
Alton 2015 analysed the 136 participants (97% of total originally
randomised) who received at least one dose of the study agent
on an ITT basis; 116 (83%) participants received a minimum
of nine doses of the study agent and comprised the per-protocol
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population (Alton 2015). Eight participants receiving placebo and
16 participants from the active group withdrew from the study
and reasons were given for all of these. The only endpoint reported
as ITT is relative change in FEV1 % predicted, whereas all other
outcomes are analysed as per protocol (Alton 2015). For the per-
protocol endpoints, there is a potential risk of bias.
Moss 2004 randomised 42 participants; 37 (88%) received at least
one dose of study drug andhadoutcomemeasures reported, and35
(83%) completed all three doses of the study agent (Moss 2004).
It is not stated whether those who withdrew had been allocated
the active or placebo treatment. Results were pooled for all 37
participants receiving at least one dose of study drug. Follow up
was complete for these participants formost endpoints to 150days,
but only 35 participants underwent HRCT lung scans, and just
10 had vector-specific CFTR gene expression assessed, resulting
in a high risk of potential bias (Moss 2004).
Moss 2007 randomised 109 participants; 102 (94%) received at
least one dose of the study drug and had outcome measures re-
ported (Moss 2007). Reasons for withdrawal or their treatment
allocation were not reported for the seven participants who did not
receive the study drug post randomisation. Respiratory function
data were reported to 90 days for all 102 participants receiving the
study drug. Four participants receiving the study drug discontin-
ued follow up after day 90 and before day 210; one participant
from the active group and three from the placebo group withdrew
(reasons given). Data on induced sputum inflammatory markers
were reported for 97 participants receiving the study drug (89%
of those randomised) (Moss 2007). We deemed this study to have
a low risk of bias from incomplete outcome data.
Selective reporting
Some secondary endpoints from two studies remain unreported,
which presents the potential for a risk of bias (Alton 2015; Moss
2007). We judged the remaining two studies to have an unclear
risk of reporting bias (Alton 1999; Moss 2004).
Other potential sources of bias
In Moss 2004, the placebo group had significantly more 1F508
homozygous participants (77%) than theCFTR gene replacement
group (25%) (P = 0.01), which could affect the validity of this
study due to the potential for gene replacement therapy to be more
effective in participants with certain CFTR gene abnormalities
versus others (Moss 2004).
Effects of interventions
Primary outcomes
1. Respiratory exacerbations
Three studies reported on this outcome (Alton 2015; Moss 2004;
Moss 2007). As the studies examined different time scales (150
days, 210 days and 11 to 12 months), and additionally Alton
examined number of participants rather than episodes and did not
differentiate between the use of oral and intravenous antibiotics,
it is not possible to combine these data in a single meta-analysis.
BothMoss studies reported on the number of respiratory exacerba-
tions requiring intravenous antibiotics (Moss 2004; Moss 2007).
Neither study found a significant difference between groups, ei-
ther at 150 days RR 1.70 (95% CI 0.50 to 5.79) or at 210 days
RR 1.33 (95% CI 0.62 to 2.89) (Analysis 1.1). Alton reported on
the number of participants receiving additional antibiotics (oral
or intravenous) between 11 and 12 months; they reported no sig-
nificant difference between treatment groups, MD 1.06 (95% CI
0.73 to 1.53) (Analysis 1.2) (Alton 2015).
2. Lung function testing
All four studies reported lung function testing as a measure of
effectiveness but presented their results using different measures.
Three studies reported at time points between 14 days and 12
months following initial dose, (Alton 2015; Moss 2004; Moss
2007). One study reported lung function at six hours post-dose
to monitor for adverse effects (Alton 1999). This meant that there
are limited opportunities to combine data in a meta-analysis.
a. Forced expiratory volume at one second (FEV1)
Three studies reported results for FEV1 (L) (Alton 1999; Moss
2004; Moss 2007).
Alton 1999 reported a fall in FEV1 at six hours post-dose (Alton
1999). There was no significant difference between active (n = 8)
and placebo (n = 8) groups, MD -1.4 L (95% CI -3.07 to 0.27)
(Analysis 1.3).
Moss 2004 reported change in FEV1 (L) from baseline at 30 days,
60 days, 90 days, and 150 days (Moss 2004). Moss 2007 reported
change this at 14 days, 30 days, 45 days, 60 days, 75 days and 90
days (Moss 2007). As the participants inMoss 2004, but notMoss
2007, received a third dose of CFTR gene replacement or placebo
on Day 60, meta-analysis was only possible on data from Day 30
and Day 60 compared to baseline, and not at subsequent time
points. AtDay 30, the earlier study demonstrated a significant im-
provement in favour of the gene therapy group (n = 20) compared
to the placebo group (n = 17), MD 0.14 L (95% CI 0.02 to 0.26)
(Moss 2004). However, at the same time point Moss 2007 did not
show a significant improvement, gene therapy group (n = 51) and
placebo group (n = 51), MD 0.03 (95% CI -0.05 to 0.11) (Moss
2007). Combined data for both Moss studies show no significant
difference between gene therapy (n = 71) and placebo (n = 68 )
groups, MD 0.06 (95% CI 0.00 to 0.13) (Analysis 1.3).
At Day 60, Moss 2004 reported no significant difference between
gene therapy (n = 19) and placebo (n = 17) groups on change
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in FEV1 (L) from baseline, MD 0.05 L (95% CI -0.12 to 0.22)
(Moss 2004). At the same time point, Moss 2007 also showed
no significant difference between treatment groups (gene therapy
n = 51; placebo n = 51), MD -0.07 (95% CI -0.15 to 0.01)
(Moss 2007). Combined data for gene therapy groups (n = 70) and
placebo groups (n = 68) at Day 60 show no significant difference,
MD -0.05 L (95% CI -0.12 to 0.02) (Analysis 1.3).
At subsequent time points (data not presented in the meta-analy-
sis), there were no significant differences in the change in absolute
FEV1 from baseline demonstrated in either Moss 2004 (90 days
and 150 days) or Moss 2007 (45 days, 60 days, 75 days and 90
days) (Moss 2004; Moss 2007); furthermore, these data cannot be
pooled due to different study regimens.
The two Moss studies reported change in FEV1 % predicted (
Moss 2004; Moss 2007). At Day 30, the Moss 2004 reported no
significant difference between the groups (gene therapy n = 20;
placebo n = 17) in change in FEV1 %predicted,MD2.99% (95%
CI -0.44 to 6.42) (Moss 2004). At the same time point, Moss
2007 also reported no significant difference between the groups
(gene therapy n = 51; placebo n = 51), MD 0.80% (95% CI -1.50
to 3.10) (Moss 2007). Combined data for the two Moss studies
at Day 30 show no significant difference between groups (gene
therapy n = 71; placebo n = 68), MD 1.48% (95% CI -0.43 to
3.39) (Analysis 1.4).
At Day 60, Moss 2004 reported no significant difference between
groups (gene therapy n = 19; placebo n = 17) for the change from
baseline in FEV1%predicted,MD0.39% (95%CI -4.31 to 5.09)
(Moss 2004). At the same time point, Moss 2007 significantly
favoured placebo (n = 51) over gene therapy (n = 51), MD -
2.69% (95% CI -5.14 to -0.24) (Moss 2007). Combined data for
these two studies at Day 60 show no significant difference between
groups (gene therapy n = 70; placebo n = 68), MD -2.03% (95%
CI -4.21 to 0.14) (Analysis 1.4).
At subsequent time points there were no significant differences in
change in FEV1 %predicted from baseline demonstrated in either
study and the data cannot be pooled for analysis (Moss 2004;Moss
2007).
b. Forced vital capacity (FVC)
Four studies reported different measures of FVC at a range of time
points (Alton 1999; Alton 2015; Moss 2004; Moss 2007).
Alton 1999 reported a fall in FVC (L) at six hours post-dose, but
there was no significant difference found between the gene therapy
group (n = 8) and the placebo group (n = 8), MD -1.70 L (95%
CI -3.27 to -0.13) (Alton 1999).
Both Moss studies assessed the change in FVC (L) from baseline
at Day 30 and Day 60 (Moss 2004; Moss 2007). At Day 30,
the earlier study reported no significant difference between the
gene therapy group (n = 20) and placebo group (n = 17), MD
0.13 L (95% CI -0.02 to 0.28) (Moss 2004). At this time point
Moss 2007 also demonstrated no significant difference between
the groups (gene therapy n = 51; placebo n = 51) MD -0.01 L
(95% CI -0.09 to 0.07) (Moss 2007). Combined data for the two
Moss studies at Day 30 show no significant difference between
the gene therapy group (n = 71) and placebo group (n = 68),
MD 0.02 L (95% CI -0.05 to 0.09) (Analysis 1.5). At Day 60,
Moss 2004 reported no significant difference between the groups
(gene therapy n = 19; placebo n = 17), MD 0.02 L (95% CI -
0.16 to 0.20) (Moss 2004). LIkewise, Moss 2007 also reported
no significant difference between the groups (gene therapy n =
51; placebo n = 51), MD -0.07 L (95% CI -0.15 to 0.01) (Moss
2007). Combined data at Day 60 show no significant difference
between gene therapy (n = 70) and placebo (n = 68), MD -0.06 L
(95% CI -0.13 to 0.02) (Analysis 1.5). At later time points there
remained no significant difference in the change from baseline in
FVC (L) when comparing CFTR gene replacement to placebo in
either study; these data were not suitable for pooling in a meta-
analysis.
Alton 2015 reported the change in FVC % predicted from base-
line at monthly intervals up to 12 months (Alton 2015). Alton
demonstrated a significant post-treatment effect in favour CFTR
gene replacement therapy compared to placebo: at two months
(gene therapy n = 60; placebo n = 52), MD 2.70% (95% CI 0.13
to 5.27); at three months (gene therapy n = 59; placebo n = 53),
MD 3.96% (95% CI 1.34 to 6.58); at 11 months (gene therapy n
= 58; placebo n = 52), MD 3.18% (95% CI 0.63 to 5.73); and at
12months (gene therapy n = 60; placebo n = 54)MD3.03% (95%
CI 0.35 to 5.71) (Analysis 1.6). Data from the remaining monthly
time points showed no significant difference between treatment
groups (Alton 2015).
c. Relative change in FEV1 or FVC
Only one study reported on relative change in FEV1 % predicted
as the primary endpoint, again at monthly intervals (Alton 2015).
Results demonstrated small but significant benefits with gene re-
placement therapy: at two months (gene therapy n = 60; placebo n
= 52), MD 3.05% (95% CI 0.14 to 5.96); at three months (gene
therapy n = 59; placebo n = 53), MD 3.41% (95% CI 0.26 to
6.56); and at 12 months (gene therapy n = 60; placebo n = 54),
MD 3.66% (95% CI 0.15 to 7.17) (Analysis 1.7). There was no
significant difference between treatment groups at the remaining
monthly time points (Analysis 1.7) (Alton 2015).
d. Other relevant lung function tests (e.g. infant lung
function tests and lung clearance index)
One study reported on gas transfer (Alton 1999). This study re-
ported a small but significant reduction in gas transfer in the
CFTR gene replacement group, mean (SD) 7.5% (7.6), but not
the placebo group, mean (SD) 1.6% (7.6) (P < 0.05) when mea-
sured on Day 2, which returned to baseline values when measured
on Day 29, but did not present any actual data for this time point
(Alton 1999).
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Alton 2015 reported a non-significant treatment effect for diffu-
sion capacity of the alveolar capillary membrane (KCOc), stan-
dardised treatment effect 0.23 (95% CI -0.17 to 0.63) (P = 0.257)
and for transfer factor of the lung for carbon monoxide (TLCOc),
standardised treatment effect 0.21 (95% CI -0.19 to 0.60) (P =
0.302) (both values corrected for haemoglobin concentrations)
(Alton 2015). The same study also reported no significant differ-
ence in lung clearance index between treatment groups, standard-
ised treatment effect 0.26 (95% CI -0.13 to 0.66) (P = 0.187);
or on the mid-expiratory flow between 25% and 75% of FVC
(MEF25−75%) for which the mean (SD) for the CFTR gene re-
placement group was -0.012 (0.395) and for the placebo group -
0.08 (0.389), standardised treatment effect 0.18 (95% CI -0.21
to 0.56) (P = 0.362) (Alton 2015). They did not present values
for each treatment group for these additional measures of lung
function to include in the analysis (Alton 2015).
3. Survival
This was not reported as a specific outcome measure in any of the
included studies. There were no deaths reported in either active
or placebo groups in three studies (Alton 1999; Alton 2015; Moss
2004). In the remaining study, one participant in the placebo
group died of an unrelated motorcycle accident (Moss 2007).
Secondary outcomes
1. Number of days as a hospital inpatient (or number of
inpatient episodes)
No study reported the number of days as a hospital inpatient.
Moss 2004 did however report the number of inpatient episodes
within 150 days (Moss 2004); there was no significant difference
between groups (gene therapy n = 20; placebo n = 17) RR 0.85
(95% CI 0.37 to 1.94) (Analysis 1.8). It is not stated clearly in
the study report whether these episodes are independent from
each other. This outcome measure was not reported by the other
included studies (Alton 1999; Alton 2015; Moss 2007).
2. Need for extra treatment
a. Physiotherapy (duration or episodes)
This outcome was not reported in any of the included studies.
3. Adverse events
Three studies reported adverse events as number of participants
experiencing each adverse event, rather than absolute number of
adverse event episodes (Alton 1999;Moss 2004;Moss 2007). The
remaining study reported themean number of times the respective
adverse event was experienced by each participant (Alton 2015); it
has therefore not been possible to combine results from this study
with the earlier studies and insufficient data have been presented
to report on Alton 2015 independently (Alton 2015). Due to the
large number of different adverse events reported, we are only
presenting significant results in the text below; for further details,
please see the meta-analysis (Analysis 1.9).
a. Mild (e.g. sore throat, hoarse voice, dry mouth)
Neither Alton study showed a difference between the active and
placebo groups in terms of mild adverse events. Alton 1999 pre-
sented the following events all occurring within 48 hours of dos-
ing as mild: cough; wheeze; or tight chest and data for these
events were pooled, making comparisons with other studies diffi-
cult (Alton 1999). Alton 2015 reported on headache and upper
airway symptoms over the 12-month study period (Alton 2015).
Both Moss studies individually recorded mild adverse events as
rhinitis, pharyngitis, headache and sinusitis; again no significant
differences between active andplacebo groupswere reported (Moss
2004; Moss 2007).
b. Moderate (e.g. wheeze, cough, fever, local allergic reaction)
Alton 1999 reported a significant increase in influenza-type symp-
toms in the CFTR gene replacement group resolving within 30
hours of dosing, RR 7.00 (95% CI 1.10 to 44.61) (Alton 1999).
Alton 2015, one participant in each treatment group experienced
“flu-like” symptoms; however this was defined as occurring fol-
lowing four or more treatment doses. It is not clear from the study
why “flu-like” symptoms were only recorded after four or more
treatment doses (Alton 2015). Alton 2015 assessed adverse events
by the following predefined categories: lower airway symptoms,
gastrointestinal symptoms, elevated liver function tests, haema-
turia and isolated raised inflammatory markers. They reported no
significant difference between treatment groups for either total
number of events or for specific adverse events by the aforemen-
tioned categories over 12 months. Data for the number of partici-
pants experiencing lower airway symptoms following four or more
treatment doses were presented and have been included in analysis
(Analysis 1.9); insufficient data were presented for the remaining
categories for inclusion in our analyses (Alton 2015).
Moss 2004 assessed abdominal pain, asthma, chest pain, cough,
increased cough, dyspnoea, fatigue, fever, decreased lung function
and increased sputum, with no significant differences between
active and placebo groups in any outcome to 150 days (Moss
2004).
Moss 2007 reported abdominal pain, asthma, increased cough,
dyspnoea, fever, decreased lung function, and increased sputum;
and also found no significant difference between groups to 210
days (Moss 2007).
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c. Severe (e.g. coughing up blood (haemoptysis), collapsed
lung (pneumothorax), chest infection, systemic allergic
reactions)
Alton 1999 reported no severe adverse events in either the CFTR
gene replacement or placebo groups (Alton 1999). There were
no significant differences in incidence of severe adverse events
between the groups in eitherMoss study (Moss 2004;Moss 2007).
Alton 2015 reported six serious adverse events, all occurring in the
CFTR gene therapy group. Only one event (admission to hospital
with flu-like illness, pulmonary exacerbation and new isolate of
MRSA within 24 hours of study bronchoscopy) was considered
by their Data Monitoring and Ethics Committee and the Trial
Steering Committee to be related to the study procedure (Alton
2015).
4. Quality of life
Only Alton 2015 reported on health-related quality of life (QoL)
using the Cystic Fibrosis Questionnaire - Revised (CFQ-R) (Alton
2015). The study reportedno significant post-treatment difference
between treatment groups (CFTR gene therapy n = 61; placebo n
= 54) for either physical functioning, MD 1.82 (95% CI -4.75 to
8.39) or respiratory symptoms, MD 2.08 (95% CI -3.06 to 7.22)
(Alton 2015).
5. School or work attendance*
This outcome was not reported in any of the included studies.
6. Nutritional parameters
a. Weight
Only Alton 2015 reported on this outcome and found no clini-
cally relevant changes in weight; however, it did not provide post-
treatment data to analyse further (Alton 2015).
b. Body mass index (BMI)
This endpoint was only reported by Alton 2015, but no data were
provided to allow analysis of this outcome; there were no clinically
relevant changes in BMI (Alton 2015).
c. Height
This outcome was not reported in any of the included studies.
7. Acquisition of newly cultured respiratory pathogens
a. Pseudomonas aeruginosa
Two studies reported on this outcome (Alton 2015; Moss 2004).
Alton 2015, 28 out of 60 (46.7%) participants in the CFTR
gene therapy group were colonised with Pseudomonas aeruginosa
(P. aeruginosa) at baseline compared to 27 out of 54 (50%) par-
ticipants in the placebo group. No data were presented for the
number of participants who were culture positive either at specific
time points during the trial or at the end of the trial; but Alton
reported that there were no clinically relevant changes in sputum
microbiology, including P. aeruginosa (Alton 2015).
Moss 2004 reported on the culture of expectorated sputum at
baseline and Day 90, but data are incomplete (Moss 2004). At
baseline, 11 out of 16 (68.8%) participants in the gene therapy
group were culture positive for P. aeruginosa; at Day 90, 14 partic-
ipants from the gene therapy group were assessed and 10 of them
were positive for P. aeruginosa (71.4%). In the placebo group, four
of the eight participants assessed at baseline tested positive for P.
aeruginosa (50%); at Day 90, eight of the 12 participants assessed
tested positive for P. aeruginosa (66.7%). It is not possible to draw
any conclusions from these limited data.
b. Staphylococcus aureus
Two studies reported on this outcome (Alton 2015; Moss 2004).
Alton 2015 reported no clinically relevant changes in sputum mi-
crobiology of Staphylococcus aureus; no additional data were pro-
vided for analysis (Alton 2015).
Data collection in Moss 2004 was incomplete (Moss 2004). Of
the six of the 16 participants in the gene therapy group assessed at
baseline were culture positive for Staphylococcus aureus (37.5%).
At Day 90, three of the 14 participants from the gene therapy
group assessed were positive for Staphylococcus aureus (21.4%). In
the placebo group, three out of eight participants assessed at base-
line tested positive for Staphylococcus aureus (37.5%); at Day 90,
seven of the 12 participants assessed tested positive for Staphylo-
coccus aureus (58.3%). Again, it is not possible to draw any firm
conclusions from these limited data.
c. Haemophilus influenzae
Only Alton 2015 reported on this outcome and found no clinically
relevant changes in Haemophilus influenzae cultures (no further
details were provided) (Alton 2015).
8. Sputum rheology
This outcome was not reported in any of the included studies.
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9. Mucociliary clearance of the airway
Alton 2015 demonstrated this outcome by recording 24-hour spu-
tum weight (Alton 2015). The study reported a non-significant
difference in the change in 24-hour sputum weight between base-
line and up to 12 months post treatment between the CFTR gene
therapy group (n = 22) and the placebo group (n = 27), MD -2.96
(95% CI -7.97 to 2.05) (Alton 2015).
Alton 1999 reported simple saccharine nasal mucociliary clear-
ance, but this is not an efficacy measure for CFTR gene replace-
ment to the lung (Alton 1999).
10. Airway potential difference measurements (measuring
salt transport)
Both Alton studies reported measurements of airway potential
difference (Alton 1999; Alton 2015). These were measured in the
lower airways using a bronchoscope and catheter. Both studies
undertook bronchoscopy once before the administration of the
study drug and repeated in Alton 1999 two days after the study
drug was administered (Alton 1999) and at 28 days (plus or minus
five days) after the final (12th) dose in Alton 2015 (Alton 2015).
Alton 2015 also undertook an analysis of nasal potential difference
in a subgroup of participants who were additionally treated with
placebo or CFTR gene therapy via a nasal spray device; this has
not been included in analysis as it is not an efficacy measure for
CFTR gene replacement therapy to the lung (Alton 2015).
a. Baseline potential difference
People with CF have a higher baseline potential difference than
people without CF (Griesenbach 2005). An effective CFTR gene
replacement intervention would therefore be expected to demon-
strate a reduction in baseline potential difference. Data for Al-
ton 1999 are for segmental bronchi, estimated from figures in the
original paper (Alton 1999). No significant change in baseline po-
tential difference was seen in either the CFTR gene replacement
group (n = 8), mean (SD) change -0.81 (9.02) millivolt (mV), or
the placebo group (n = 8), mean (SD) change 2.53 (6.48) mV
(Alton 1999).When these data are entered in the review’s analysis,
there was no difference between the groups, MD -3.34 (95% CI
-11.04 to 4.36) (Analysis 1.10).
For Alton 2015, we calculated change in baseline potential dif-
ference from baseline and post-treatment data provided (mean
(SEM)); assuming a correlation coefficient (Corr) of 0.9 to esti-
mate the SD. There was no significant difference between treat-
ment groups (CFTR gene therapy group n = 10; placebo n = 7),
MD -0.30 (95% CI -2.90 to 2.30) (Analysis 1.10). Sensitivity
analyses at a range of values for Corr also showed no statistical
difference between treatment groups (Alton 2015). Alton 2015
demonstrated no significant difference in post-treatment (after 12
months) bronchial potential difference between treatment groups,
MD 1.70 (95% CI -3.50 to 6.90) (Analysis 1.12). Data presented
for this study are the mean of tracheal and all bronchial measure-
ments (Alton 2015).
b. Response to perfusion with amiloride
Since sodium absorption is increased in people with CF, a greater
reduction in potential difference from baseline is seen in re-
sponse to amiloride in participants with CF than in those with-
out CF (Griesenbach 2005). Thus effective CFTR gene replace-
ment should reduce the fall in potential difference seen following
amiloride. Alton 1999 demonstrated no significant change in re-
sponse to perfusion with amiloride in either the CFTR gene re-
placement group (n = 8) mean (SD) change -12.6 (14.66) or the
placebo group (n = 8) mean (SD) change -16.50 (13.17) (Alton
1999). Our analysis showed no difference between the groups,
MD 3.90 (95% CI -9.76 to 17.56) (Analysis 1.11).
c. Response to perfusion with a zero chloride solution
The response to zero or low chloride secretion following prior
perfusion with amiloride is the airway potential difference mea-
surement that is the most effective discriminator between CF and
non-CF participants (Alton 1999;Griesenbach 2005). Both Alton
studies reported this as a summed response to low chloride solu-
tion and isoprenaline (Alton 1999; Alton 2015). A separate con-
trol group of participants without CF had a mean (SD) response
of 10.70 (4.11). Data from Alton 1999 have been estimated from
figures in the original paper (Alton 1999). The study reported
that in the CFTR gene replacement group there was a significant
improvement following perfusion with a zero chloride solution,
mean (SD) 5.4 (3.82) (P < 0.05), with no significant change in
the placebo group, mean (SD) -1.46 (2.29) (Alton 1999). This
change in the CFTR replacement group (n = 8) was significantly
different from that in the placebo group (n = 8) (P < 0.0001), MD
6.86 (95% CI 3.77 to 9.95) (Analysis 1.11).
In Alton 2015, participants in the placebo group (n=7) had a
median (range) change of 3.1mV (9.3 to -1.2) compared to a
median (range) change of -1.3mV (4.0 to -5.8) (P = 0.032) in the
CFTRgene therapy group (n = 10). Themean change in bronchial
chloride responses as well as pre- and post-treatment data for each
individual participant were presented in graphical form; aggregate
data were not available for analysis (Alton 2015).
11. Measures of gene expression
a. Quantitative reverse transcription polymerase chain
reaction (rtPCR) to measure vector-specific CFTR messenger
ribonucleic acid (mRNA) production
This outcome was reported in three studies, but at different time
points (Alton 1999; Alton 2015; Moss 2004). In Alton 1999,
bronchial brushings were performed two days following the single
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dose of CFTR gene replacement or placebo. No vector specific
mRNA could be detected by this measure in either theCFTR gene
replacement group (n = 8), or the placebo group (n = 8) (Alton
1999). In Alton 2015, bronchial brushings were performed in a
subgroup of participants at 28 days, plus or minus five days, after
the 12th dose; four participants’ measurements were taken beyond
this time window due to clinical instability and one participant’s
bronchoscopy was performed after the sixth dose due to with-
drawal from the study. No vector-specific mRNA was detected
in either the CFTR gene replacement group (n = 14) or placebo
group (n = 7) (Alton 2015). In Moss 2004, six out of the 20 par-
ticipants in the active group and two out of the 17 participants in
the placebo group had bronchial brushings performed 30 to 60
days after the third dose of the study drug. As with the previous
two studies, no vector specific mRNA could be detected in any
participant sampled (Moss 2004).
b. Any other method of measuring gene expression
Only Alton 2015 reported on this outcome and isolated DNA
from bronchial brushings in the subgroup of participants who
underwent bronchoscopy (Alton 2015). They demonstrated an
increase in vector-specificDNA in 12 out of 14 participants (86%)
in the CFTR gene replacement group compared to readings below
the limit of quantification in the seven participants in the placebo
group (P = 0.001) (Alton 2015).
12. Measures of CFTR protein expression
Only Alton 1999 measured chloride efflux in cells obtained by
bronchial brushing, by measuring changes in 6-methoxy-N-(-
sulphopropyl) quinolium (SPQ) fluorescence (Alton 1999). Any
increase in CFTR protein expression following the delivery of the
study drug would result in an increased efflux of the SPQ fluores-
cence. There was no significant difference in SPQ efflux between
the two groups (CFTR gene therapy n = 6; placebo n = 7), MD
0.3 mMs−1 (95% CI -0.12 to 0.72) (Analysis 1.13). Data for the
placebo group were estimated from a figure in the original paper.
The original paper reports a significant increase in efflux (P < 0.05)
in the active, but not in the placebo group (Alton 1999).
13. Radiological measures of lung disease
a. Validated chest radiograph scores
This outcome was only reported in Alton 1999, which used the
previously validated CF Northern score (Conway 1994). The in-
vestigators report “no significant change from baseline” at Day 29,
but the data are not shown (Alton 1999).
b. Validated computerised tomogram (CT) score
Two studies reported this outcome measure (Alton 2015; Moss
2004). In Alton 2015, high resolution CT scans were obtained
from participants at baseline and at 28 days (plus or minus five
days) after dose 12 of the study drug (Alton 2015). Investiga-
tors then studied the following features: extent of bronchiectasis
(scored per lobe on a range of 0 to 3); severity of bronchiectasis
and bronchial wall thickness (scored per lobe on a range of 0 to
4); small and large airway mucus plugs (scored per lobe on a range
of 0 to 2); and gas trapping on expiratory CT (scored on a per-
centage basis). Results demonstrated a significant improvement in
CT gas trapping for CFTR gene replacement therapy compared to
placebo,MD -3.49 (95%CI -6.96 to -0.03) (Alton 2015). For the
remaining features (extent of bronchiectasis, severity of bronchiec-
tasis, bronchial wall thickening and small and large airway plugs),
there was no significant difference in the change in score between
treatment groups (Alton 2015).
InMoss 2004, participants underwent a high resolutionCT scan at
baseline and on Day 90, 30 days after the third dose of study drug
had been administered (Moss 2004). The CT scans were scored
on a scale from 0 to 100 using an algorithm that had not been
previously validated andwas developed for this study.Therewas no
significant difference between the groups in terms of change inCT
score from baseline at Day 90, with the CFTR gene replacement
group (n = 18) mean (SD) -1.00 (3.00), placebo group (n = 17)
mean (SD) 0.00 (6.00); MD -1.00 (95% CI -4.17 to 2.17) (
Analysis 1.14).
These data must be treated with caution as the scoring system had
not been previously validated.
D I S C U S S I O N
Summary of main results
Four randomised controlled trials met the inclusion criteria for
this review. They compared cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene replacement to placebo delivered
to the lungs of participants with cystic fibrosis (CF) (Alton 1999;
Alton 2015; Moss 2004; Moss 2007).
Two studies examined a liposome-basedCFTRgene delivery agent
(Alton 1999; Alton 2015). In Alton 1999 participants received
a single dose of study drug with follow up for 29 days (Alton
1999) and in Alton 2015 participants received monthly doses for
12 months with follow up for up to 13 months (Alton 2015). In
Alton 2015, at 12 months participants who received CFTR gene
transfer agents had an improvement in relative change in forced
expiratory volume at one second (FEV1) % predicted compared
to those who had received placebo, MD 3.66 (95% CI 0.15 to
7.17) (Analysis 1.7). This was also demonstrated after two and
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three months, but not at the remaining time points over the 12-
month study period (Alton 2015). Alton 2015 also demonstrated
significant improvements in FVC (% predicted) at two, three, 11
and 12 months in participants receiving CFTR gene replacement
therapy compared to placebo. Alton 1999 reported an significant
increase in FVC (L) in the placebo group compared to the treat-
ment group at up to 24 hours. With regards to adverse events,
Alton 1999 reported “influenza-like” symptoms in seven out of
eight participants who received the CFTR gene transfer reagents
(Alton 1999). In the larger Alton 2015, these symptoms were re-
ported in one participant who had taken at least four doses and
one in the placebo arm (Alton 2015).
The two Moss studies used a viral CFTR gene delivery system
(AAV)with followup for 150 to 210 days respectively (Moss 2004;
Moss 2007). These studies were of similar design, although three
doses were given in the Moss 2004 and two doses in Moss 2007.
There were no significant differences in rate of exacerbation be-
tween the treatment group and placebo in either study. Moss 2004
demonstrated a significant improvement in respiratory function
(FEV1) 30 days after participants had received their first dose of
gene therapy agent. This finding was not confirmed inMoss 2007
or in our meta-analysis (Moss 2004; Moss 2007). Neither Moss
study nor our meta-analysis of FVC (L) showed any significant
difference between treatment and placebo groups at either 30 days
or two months (Analysis 1.5).
No study reported on survival; however, no deaths were reported
in three of the studies and the single death reported in one study
was not treatment related.
Overall completeness and applicability of
evidence
Four trials recruiting 302 participants with CF were included in
this review; three trials recruited a mixture of males and females
aged 12 years and over (Alton 2015; Moss 2004; Moss 2007)
and one recruited only adult males due to regulatory restrictions
(Alton 1999). Themean age of participants in the four studies was
24.5 years. Homozygous F508 was the commonest genotype
in the studies. There are insufficient data reported in the studies
for some outcomes considered to be important for this review:
oral antibiotics (days or episodes); number of days as a hospital
inpatient; need for extra treatment (physiotherapy); school orwork
attendance; height; and sputum rheology.
Quality of the evidence
All included studies had a parallel design. Overall there were mi-
nor issues with quality, in particular risk of bias from conceal-
ment, allocation and randomisation. Methods of randomisation
and allocation concealment are specified in just one study (Alton
2015); in the remaining studies, they are unclear (Alton 1999;
Moss 2004; Moss 2007). In Moss 2004, 83% of randomised par-
ticipants received all three doses of study drug and it is not stated
whether withdrawals had been originally allocated to the active or
the placebo group (Moss 2004). Post-allocation withdrawal also
occurred in Moss 2007, but to a lesser extent study (Moss 2007).
In Alton 2015, 83% of randomised participants received at least
nine doses of study drug and were included in the per-protocol
analysis. Reason for withdrawal was described up to the ninth
dose, but it is not clear if participants withdrew after receiving
nine doses (Alton 2015). In Alton 2015, measures were taken and
described to ensure adequate blinding for the participants, but this
was a challenge as the placebo was a quite distinct solution (saline)
compared to the gene therapy agent (Alton 2015).
Potential biases in the review process
The review authors conducted a comprehensive literature search
of online journal databases using the Cystic Fibrosis and Genetic
Disorders Review Group’s Cystic Fibrosis Trials Register and the
ongoing online trials database (ClinicalTrials.gov). In addition,
authors approached known researchers in the field for relevant un-
published information and individual participant data. Two au-
thors (TWRL and KWS) selected eligible trials and extracted data
for the original review and earlier updates. For the update in 2016,
two authors (LAP and JCP-D) independently undertook further
study selection and data extraction. The analyses of this update
were undertaken by one review author (AA). This methodological
approach ensured that risks of bias in the review process were kept
to a minimum.
Agreements and disagreements with other
studies or reviews
There are no other systematic reviews of topical gene replacement
therapy for CF.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
While the meta-analysis of most respiratory function tests showed
no difference between treatment and placebo groups, the most
recent study, Alton 2015, demonstrated a benefit in relative change
in FEV1 % predicted and FVC % predicted at 12 months for
participants receiving CFTR gene replacement therapy compared
to those receiving placebo (Alton 2015). Concerns over safety with
“flu-like” symptoms in most participants in the Alton 1999 study
were not reported on repeated use in Alton 2015 (Alton 1999;
Alton 2015). There was no other evidence of positive impact on
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outcomes, in particular improved quality of life, reduced treatment
burden or exacerbations (Alton 2015). The limited evidence of
efficacy does not support this as a routine therapy at present.
There was no evidence of efficacy for viral-mediated gene delivery
from the remaining two included studies (Moss 2004;Moss 2007).
Implications for research
Clinical studies examining the use of CFTR gene transfer reagents
for CF lung disease should include outcome measures that are
relevant to people with CF as well as clearly defined surrogate
measures of efficacy. It is imperative that future studies of estab-
lished or novel gene therapy reagents use a robust study design
with clearly defined endpoints and adequate power. These studies
must be reported in a full and transparent manner to enable the
incorporation of data into systematic reviews. A clear cost analy-
sis is essential for any emerging therapies, as this is likely to be a
significant factor. In future updates of this review, we will include
this as a pertinent secondary outcome measure.
A C K N OW L E D G E M E N T S
We would like to acknowledge the Cochrane Cystic Fibrosis &
Genetic Disorders Review Group, in particular Nikki Jahnke and
Tracey Remmington. We thank Ashley Jones and Sarah Nolan for
invaluable statistical support and the investigators, Richard Moss
andEric Alton, andAlisonHeald, TargetedGenetics Corporation,
for their interest and help with the study.
R E F E R E N C E S
References to studies included in this review
Alton 1999 {published data only}
∗ Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL,
Phillips J, et al. Cationic lipid-mediated CFTR gene
transfer to the lungs and nose of patients with cystic fibrosis:
a double-blind placebo-controlled trial. The Lancet 1999;
353(9157):947–54. [CFGD Register: BD11a; ]
Davies MG, Stern M, Geddes DM, Alton EWFW.
Reduction in sputum inflammatory cells and IL-8 following
pulmonary administration of liposome mediated CFTR
gene transfer in CF subjects [abstract]. Thorax 1998;53
(Suppl 4):A14. [CFGD Register: BD11b; ]
Stern M, Phillips J, Jaffe A, Farley R, Chadwick S, Davies
J. A double blind placebo controlled trial of pulmonary
and nasal administration of liposome-mediated CFTR gene
transfer in CF subjects [abstract]. American Journal of
Respiratory and Critical Care Medicine 1998;157(3 Suppl):
A564. [CFGD Register: BD11d; ]
Stern M, Phillips J, Jaffe A, Farley R, Chadwick S, Davies J,
et al. A double blind placebo controlled trial of pulmonary
and nasal administration of liposome-mediated CFTR gene
transfer in CF subjects [abstract]. Thorax 1997;52(Suppl
6):A3. [CFGD Register: BD11c; ]
Alton 2015 {published data only}
Clinical study protocol - a randomised, double-blind,
placebo-controlled phase 2b clinical trial of repeated
application of gene therapy in patients with cystic
fibrosis. Short title: repeated application of gene
therapy in CF patients. Version: 3. Date 26.03.2012
[online]. http://www.eme.ac.uk/funded_projects/PDFs/
111425protocol.pdf 2013. [CFGD Register: BD180d; ]
Project brief: A randomised double-blind placebo controlled
phase 2b clinical trial of repeated application of gene
therapy in patients with cystic fibrosis [online]. http://
www.eme.ac.uk/funded_projects/PDFs/111425info.pdf
2013. [CFGD Register: BD180c; ]
Alton E. The UK Gene Therapy Trial [abstract]. Pediatric
Pulmonology 2014;49 Suppl 38:153, Abstract no: S10.1.
[CFGD Register: BD180i; ]
Alton E, Armstrong D, Bayfield K, Bilton D, Boyd A,
Cheng S, et al. A randomized, double-blind, placebo-
controlled trial of repeated nebulisations of non-viral CFTR
gene therapy in patients with cystic fibrosis [abstract].
Pediatric Pulmonology 2015;50 Suppl 41:262, Abstract no:
192. [CENTRAL: 1092195; CFGD Register: BD180m;
CRS: 5500135000001384; ]
∗ Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton
D, Bloomfield EV, et al. Repeated nebulisation of non-
viral CFTR gene therapy in patients with cystic fibrosis: a
randomised, double-blind, placebo-controlled, phase 2b
trial. The Lancet. Respiratory Medicine 2015;3(9):684–91.
[CFGD Register: BD180j; CRS: 5500135000000005;
PUBMED: 26149841]
Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton
D, Bloomfield EV, et al. Supplementary appendix to
“Repeated nebulisation of non-viral CFTR gene therapy
in patients with cystic fibrosis: a randomised, double-
blind, placebo-controlled, phase 2b trial” [online]. The
Lancet. Respiratory Medicine 2015:Epub ahead of print.
[CENTRAL: 1081473; CFGD Register: BD180k; CRS:
5500135000001320; ]
Alton EW, Ashby D, Boyd C, Cheng S, Cunningham S,
Davies JC, et al. Update on the UK CF gene therapy trial
[abstract]. Pediatric Pulmonology 2012;47 Suppl 35:309,
Abstract no: 245. [CFGD Register: BD180a; ]
Alton EW, Boyd AC, Cheng SH, Cunningham S, Davies
JC, Gill DR, et al. A phase 2B double-blind, placebo-
controlled trial of non-viral mediated gene therapy for CF
[abstract]. Pediatric Pulmonology 2013;48 Suppl 36:293,
Abstract no: 245. [CENTRAL: 921690; CFGD Register:
16Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
BD180e; CRS: 5500125000000402; ]
Alton EW, Boyd AC, Cheng SH, Cunningham S, Davies
JC, Gill DR, et al. A randomised, double-blind, placebo-
controlled phase IIB clinical trial of repeated application
of gene therapy in patients with cystic fibrosis. Thorax
2013;68(11):1075–7. [CENTRAL: 964699; CFGD
Register: BD180f; CRS: 5500125000000726; PUBMED:
23525080]
Bayfield KJ, Alton EW, Boyd A, Cheng SH, Cunningham
S, Davies JC, et al. Lung function outcome measures in a
multidose trial of non-viral gene therapy in patients with
CF [abstract]. Pediatric Pulmonology 2014;49 Suppl 38:
364-365, Abstract no: 410. [CENTRAL: 1012535; CFGD
Register: BD180g; CRS: 5500131000000194; ]
Elgmati HI, Alton EW, Armstrong DK, Bayfield KJ, Boyd
A, Cheng SH, et al. Cardiopulmonary exercise testing
(CPET) as an outcome measure in cystic fibrosis clinical
trial [abstract]. Pediatric Pulmonology 2014;49 Suppl 38:
366, Abstract no: 413. [CENTRAL: 1012536; CFGD
Register: BD180h; CRS: 5500131000000195; ]
Griesenbach U, Alton E, Armstrong D, Boyd A, Brand J,
Calcedo R, et al. Repeated administration of the non-viral
gene transfer agent PGM169/ GL67A does not induce anti-
CFTR or anti-PLASMID immune responses [abstract].
Pediatric Pulmonology 2015;50 Suppl 41:283, Abstract no:
244. [CENTRAL: 1092181; CFGD Register: BD180l;
CRS: 5500135000001377; ]
Hyde SC. Non-viral CFTR gene delivery to the lungs
of cystic fibrosis patients [abstract]. Human Gene
Therapy 2013;24(12):A8. [CENTRAL: 1064275; CFGD
Register: BD180n; CRS: 5500050000000364; EMBASE:
71277055]
NCT01621867. A randomised, double-blind, placebo-
controlled phase 2B clinical trial of repeated application
of gene therapy in patients with cystic fibrosis. http://
clinicaltrials.gov/show/NCT01621867 2013. [CFGD
Register: BD180b; ]
Moss 2004 {published data only}
Moss RB, Aitken M, Clancy J, Milla C, Rodman D,
Spencer T, et al. A multicenter, double-blind, placebo
controlled, phase II study of aerosolized TGAAVCF in
cystic fibrosis patients with mild lung disease [abstract].
Pediatric Pulmonology 2002;34(Suppl 24):250–1. [CFGD
Register: BD17a; ]
∗ Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL,
Waltz D, et al. Repeated adeno-associated virus serotype 2
aerosol-mediated cystic fibrosis transmembrane regulator
gene transfer to the lungs of patients with cystic fibrosis: a
multicenter, double-blind, placebo-controlled trial. Chest
2004;125(2):509–21. [CFGD Register: BD17b; ]
Moss 2007 {published and unpublished data}
Moss RB, Heald AE, 25E01 SG. Phase 2B Trial of
Aerosolized tgAAVCF for Cystic Fibrosis [abstract]. Journal
of Cystic Fibrosis 2005;4 Suppl:S27. [CFGD Register:
BD20b; ]
Moss RB, Heald AE, 25E01 Study Group. A randomized
phase 2B study of aerosolized tgAAVCF for treatment
of cystic fibrosis [abstract]. American Thoracic Society
International Conference; 2005 May 20-25; San Diego,
USA. 2005:A179. [CFGD Register: BD20c; ]
∗ Moss RB, Milla C, Colombo J, Accurso F, Zeitlin
PL, Clancy JP, et al. Repeated aerosolized AAV-CFTR
for treatment of cystic fibrosis: a randomized placebo-
controlled phase 2B trial. Human Gene Therapy 2007;18
(8):726–32. [CFGD Register: BD20d; ]
Moss RB, Milla C, Colombo J, Clancy JP, Zeitlin P, Spencer
T, et al. A multicenter, double-blind, placebo-controlled,
phase 2b study of aerosolized TGAAVCF for the treatment
of cystic fibrosis [abstract]. Pediatric Pulmonology 2004;38
(Suppl 27):257. [CFGD Register: BD20a; ]
References to studies excluded from this review
Davies 2011 {published data only}
Alton E. Single dose of PGM169/GL67A in CF patients.
http://public.ukcrn.org.uk/search/StudyDetail.aspx?
StudyID=7094 Accessed on 22 September 2009. [UKCRN
ID 7094]
Alton E, Davies JC, Davies G, Lees B, Mohamedhossen
MH, Soussi S, et al. Safety evaluation of a single escalating
dose of pGM169/GL67A in the nose and lung of
individuals with cystic fibrosis. www.rbht.nhs.uk/research/
projects/?entryid31=161410&catid=651&p=1 Accessed
22 September 2009. [Royal Brompton & Harefield NHS
Trust Ref No.: 2007CF011B]
Davies JC, Davies G, Gill DR, Hyde SC, Boyd AC, Innes
AJ, et al. Safety & expression of a single dose of lipid-
mediated CFTR gene therapy to the upper & lower airways
of patients with CF. Pediatric Pulmonology 2011;46(Suppl
34):Abstract 198.
Flotte 1996 {published data only}
Flotte T, Carter B, Conrad C, Guggino W, Reynolds T,
Rosenstein B, et al. A phase I study of an adeno-associated
virus-CFTR gene vector in adult CF patients with mild
lung disease. Human Gene Therapy 1996;7(9):1145–59.
[CFGD Register: BD6; MEDLINE: 96369511]
Gill 1997 {published data only}
∗ Gill DR, Southern KW, Mofford KA, Seddon T, Huang
L, Sorgi F, et al. A placebo-controlled study of liposome-
mediated gene transfer to the nasal epithelium of patients
with cystic fibrosis. Gene Therapy 1997;4(3):199–209.
[CFGD Register: BD4c; MEDLINE: 97281425]
Gill DR, Southern KW, Mofford KA, Sorgi F, Huang L,
Higgins CF, et al. A Phase I clinical trial to assess the safety
of DNA/liposome mediated gene transfer [abstract]. Tenth
Annual North American Cystic Fibrosis Conference 1996;
Suppl 13:264. [CFGD Register: BD4a; ]
Hyde SC, Southern KW, Mofford KA, Sorgi F, Huang L,
Higgins CF, et al. Towards DNA/liposome gene therapy for
cystic fibrosis: A phase I clinical trial [abstract]. Pediatric
Pulmonology 1996;22(Suppl 13):265. [CFGD Register:
BD4b; ]
Harvey 1999 {published data only}
Harvey BG, Leopold PL, Hackett NR, Grasso TM,
Williams PM, Tucker AL, et al. Airway epithelial CFTR
17Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
mRNA expression in cystic fibrosis patients after repetitive
administration of a recombinant adenovirus see comments.
Journal of Clinical Investigation 1999;104(9):1245–55.
[CFGD Register: BD13; ]
Hyde 2000 {published data only}
∗ Hyde SC, Southern KW, Gileadi U, Fitzjohn EM,
Mofford KA, Waddell BE, et al. Repeat administration of
DNA/liposomes to the nasal epithelium of patients with
cystic fibrosis. Gene Therapy 2000;7(13):1156–65. [CFGD
Register: BD15b; ]
Southern KW, Hyde SC, Fitzjohn EM, Waddell BE,
Egan JJ, Cole JY, et al. Repeated nasal administration
of liposome-mediated CFTR gene transfer reagents; the
clinical and immunological consequences [abstract].
Pediatric Pulmonology 1997;24(Suppl 14):265. [CFGD
Register: BD15a; ]
Joseph 2001 {published data only}
Joseph PM, O’Sullivan BP, Lapey A, Dorkin H, Oren J,
Balfour R, et al. Aerosol and lobar administration of a
recombinant adenovirus to individuals with cystic fibrosis.
I. Methods, safety, and clinical implications. Human Gene
Therapy 2001;12(11):1369–82. [CFGD Register: BD16; ]
Knowles 1995 {published data only}
Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah
TL, Hu PC, et al. A controlled study of adenoviral-vector-
mediated gene transfer in the nasal epithelium of patients
with cystic fibrosis. New England Journal of Medicine 1995;
333(13):823–31. [CFGD Register: BD1; ]
Noone 2000 {published data only}
Noone PG, Hohneker KW, Gipson CA, Schwartzbach
CJ, Efthimiou J, Johnson LG, et al. Safety and biological
efficacy of a lipid-CFTR complex for gene transfer in
the nasal epithelium of adult patients with cystic fibrosis
[abstract]. Pediatric Pulmonology 1998;26(Suppl 17):260.
[CFGD Register: BD10a; ]
∗ Noone PG, Hohneker KW, Zhou Z, Johnson LG, Foy C,
Gipson C, et al. Safety and biological efficacy of a lipid-
CFTR complex for gene transfer in the nasal epithelium of
adult patients with cystic fibrosis. Molecular Therapy 2000;
1(1):105–14. [CFGD Register: BD10b; ]
Porteous 1997 {published data only}
∗ Porteous DJ, Dorin JR, McLachlan G, Davidson Smith
H, Davidson H, Stevenson BJ, et al. Evidence for safety
and efficacy of DOTAP cationic liposome mediated CFTR
gene transfer to the nasal epithelium of patients with cystic
fibrosis. Gene Therapy 1997;4(3):210–8. [CFGD Register:
BD5b; MEDLINE: 97281426]
Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H,
Davidson H, Stevenson BJ, et al. DOTAP catonic liposome
mediated CFTR gene transfer to the nasal epithelium of
patients with cystic fibrosis [abstract]. Pediatric Pulmonology
1996;22(Suppl 13):266. [CFGD Register: BD5a; ]
Wagner 1999 {published data only}
∗ Wagner JA, Messner AH, Moran ML, Daifuku R,
Kouyama K, Desch JK, et al. Safety and biological
efficacy of an adeno-associated virus vector - cystic fibrosis
transmembrane regulator (AAV-CFTR) in the cystic fibrosis
maxillary sinus. Laryngoscope 1999;109(2 Pt 1):266–74.
[CFGD Register: BD8b; ]
Wagner JA, Nepomuceno IB, Shah N, Messner AH, Moran
ML, Norbash AM, et al. Maxillary sinusitis as a surrogate
model for CF gene therapy clinical trials in patients with
antrostomies. Journal of Gene Medicine 1999;1(1):13–21.
[CFGD Register: BD8c; ]
Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ,
Flotte TR, et al. Efficient and persistent gene transfer of
AAV-CFTR in maxillary sinus [letter]. Lancet 1998;351
(9117):1702–3. [CFGD Register: BD8a; ]
Wagner 2002 {published data only}
Wagner JA, Messner AH, Friborg S, Reynolds T, Guggino
WB, Moss RB, et al. A phase II, double-blind, randomized,
placebo-controlled clinical trial of tgAAVCF in the maxillary
sinus of CF patients [abstract]. Pediatric Pulmonology 1998;
26(Suppl 17):260. [CFGD Register: BD9a; ]
Wagner JA, Messner AH, Moran ML, Guggino WB, Flotte
TR, Wine JJ, et al. A phase II, double-blind, randomized,
placebo-controlled clinical trial of tgAAVCF using maxillary
sinus delivery in CF patients with antrostomies [abstract].
Pediatric Pulmonology 1999;28(Suppl 19):223–4. [CFGD
Register: BD9b; ]
∗ Wagner JA, Nepomuceno IB, Messner AH, Moran ML,
Batson EP, Dimiceli S, et al. A phase II, double-blind,
randomized, placebo-controlled clinical trial of tgAAVCF
using maxillary sinus delivery in patients with cystic fibrosis
with antrostomies. Human Gene Therapy 2002;13(11):
1349–59. [CFGD Register: BD9c; ]
Zabner 1996 {published data only}
Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP,
Gibson RL, et al. Repeat administration of an adenovirus
vector encoding cystic fibrosis transmembrane conductance
regulator to the nasal epithelium of patients with cystic
fibrosis. Journal of Clinical Investigation 1996;97(6):
1504–11. [CFGD Register: BD18; ]
Zabner 1997 {published data only}
Zabner J, Cheng SH, Meeker D, Launspach J, Balfour R,
Perricone MA, et al. Comparison of DNA-lipid complexes
and DNA alone for gene transfer to cystic fibrosis airway
epithelia in vivo. Journal of Clinical Investigation 1997;
100(6):1529–37. [CFGD Register: BD7; MEDLINE:
97439775]
Zuckerman 1999 {published data only}
∗ Zuckerman JB, Robinson CB, McCoy KS, Shell
R, Sferra TJ, Chirmule N, et al. A phase I study of
adenovirus-mediated transfer of the human cystic fibrosis
transmembrane conductance regulator gene to a lung
segment of individuals with cystic fibrosis. Human Gene
Therapy 1999;10(18):2973–85. [CFGD Register: BD14; ]
Additional references
18Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bobadilla 2002
Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic Fibrosis:
A worldwide analysis of CFTR mutations - correlation
with incidence data and application to screening. Human
Mutation 2002;19(6):575–606.
Boucher 2004
Boucher RC. New concepts of the pathogenesis of cystic
fibrosis lung disease. European Respiratory Journal 2004;23
(1):146–58.
Conway 1994
Conway SP, Pond MN, Bowler I, Smith DL, Simmonds EJ,
Joanes DN, et al. The chest radiograph in cystic fibrosis: A
new scoring system compared with the Chrispin-Norman
and Brasfield scores. Thorax 1994;49:860–2.
Deeks 2011
Deeks J, Higgins J, Altman D on behalf of the Cochrane
Statistical Methods Group (editors). Chapter 9 Analysing
data and undertaking meta-analysis. In: Higgins JPT,
Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Elbourne 2002
Elbourne DR, Altman DG, Higgins JP, Curtin F,
Worthington HV, Vail A. Meta-analyses involving cross-
over trials: methodological issues. International Journal of
Epidemiology 2002;31:140–9.
Ferrari 2002
Ferrari S, Geddes DM, Alton EW. Barriers to and new
approaches for gene therapy and gene delivery in cystic
fibrosis. Advanced Drug Delivery Reviews 2002;54(11):
1373–93.
FitzSimmons 1993
FitzSimmons SC. The changing epidemiology of cystic
fibrosis. Journal of Pediatrics 1993;122(1):1–9.
Frederiksen 1996
Frederiksen B, Lanng S, Koch C, Hoiby N. Improved
survival in the Danish centre treated cystic fibrosis patients:
Results of aggressive treatment. Pediatric Pulmonology 1996;
21(3):153–8.
Griesenbach 2004
Griesenbach U, Geddes DM, Alton EW. Gene therapy for
cystic fibrosis: an example for lung gene therapy. Gene
Therapy 2004;11(Suppl 1):S43–50.
Griesenbach 2005
Griesenbach U, Boyd AC. Pre-clinical and clinical endpoint
assays for cystic fibrosis gene therapy. Journal of Cystic
Fibrosis 2005;4:89–100.
Griesenbach 2008
Griesenbach U. The UK gene therapy consortium research
programme [abstract]. Journal of Cystic Fibrosis 2008;7
(Suppl 3):S4.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. British Medical
Journal 2003;327(7414):557–60.
Higgins 2011
Higgins JPT, Altman DG (editors). Chapter 8: Assessing
risk of bias in included studies. In: Higgins JPT, Green
S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Jüni 2001
Jüni P, Altman DG, Egger M. Systematic reviews in
healthcare: Assessing the quality of controlled clinical trials.
British Medical Journal 2001;323(7303):42–6.
Lee 2005
Lee TW, Matthews DA, Blair GE. Novel molecular
approaches to cystic fibrosis gene therapy. Biochemical
Journal 2005;387(Pt 1):1–15.
Matsui 1998
Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy
JT, Davis W, et al. Evidence for periciliary liquid
layer depletion, not abnormal ion composition, in the
pathogenesis of cystic fibrosis airways disease. Cell 1998;95
(7):1005–15.
Ranganathan 2004
Ranganathan SC, Stocks J, Dezateux C, Bush A, Wade A,
Carr S, et al. The evolution of airway function in early
childhood following clinical diagnosis of cystic fibrosis.
American Journal of Respiratory and Critical Care Medicine
2004;169(8):928–33.
Riordan 1989
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R,
Grzelczak Z, et al. Identification of the cystic fibrosis gene:
cloning and characterization of complementary DNA.
Science 1989;245(4922):1066–73.
Rowntree 2003
Rowntree RK, Harris A. The phenotypic consequences of
CFTR mutations. Annals of Human Genetics 2003;67(Pt
5):471–85.
Southern 1996
Southern KW. Gene therapy for cystic fibrosis: current
issues. British Journal of Hospital Medicine 1996;55(8):
495–9.
Southern 2003
Southern KW, Smyth RL. Design of clinical trials in cystic
fibrosis. Lancet 2003;360:978–84.
References to other published versions of this review
Lee 2007
Lee TWR, Southern KW. Topical cystic fibrosis
transmembrane conductance regulator gene replacement
for cystic fibrosis-related lung disease. Cochrane Database
of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/
14651858.CD005599.pub2]
19Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lee 2012
Lee TWR, Southern KW. Topical cystic fibrosis
transmembrane conductance regulator gene replacement
for cystic fibrosis-related lung disease. Cochrane Database
of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/
14651858.CD005599.pub3]
∗ Indicates the major publication for the study
20Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alton 1999
Methods Double-blind placebo-controlled RCT.
Parallel design.
Duration: 2 weeks.
Single centre in UK.
Participants 16 participants (all male). Treatment group n = 8, placebo group n = 8
Mean age 26.9 years. Mean (SE) age: treatment group 27·5 (3·4) years, placebo group
26·3 (1·7) years.
Confirmed CF, FEV1 >70%, sterile.
Genotype (not split by treatment/placebo group):
F508/ F508 n = 12
F508/W1282X n = 1
F508/other (i.e., no mutation detected after screening for mutations present in 92%
to 94% of UK patients with CF) n = 3
Interventions Single dose of CFTRDNA+liposome, or liposome alone nebulised to lungs. 1 week later
administration to the nose
Outcomes Adverse events, gene expression, CFTR protein expression, airway potential difference
Notes Additional data requested from author, no additional data available. Analysed on inten-
tion-to-treat basis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no further
details given.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and outcome assessors
blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk All randomised participants assessed on
intention-to-treat basis, although data in-
complete for 4 reported endpoints
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias Unclear risk Unclear.
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Alton 2015
Methods Double-blind, placebo-controlled RCT.
Parallel design.
Duration: 1 year.
Multicentre (18 sites) in UK.
Participants 140 randomised. Confirmed CF aged 12 years and over and FEV1 50% - 90% predicted.
2 participants from each group withdrew prior to treatment start so that: treatment group
n = 76, placebo n = 60
Data available from 116 participants who received at least 9 doses: treatment group n =
62, placebo n = 54
Mean (SD) age: treatment group 23·6 (10·8) years; placebo group 26·0 (13·0) years
Gender split (total: 56 males and 60 females): treatment group 31 males and 31 females;
placebo 29 males and 25 females
FEV1 mean (SD): treatment group 69.9 (11.1); placebo group 69.0 (9.9)
Height mean (SD): treatment group 163·6 (10·9) cm; placebo group 165·0 (10·6) cm
Weight mean (SD): treatment group 61·0 (15·7) kg; placebo group 61·6 (15·6) kg
BMI mean (SD): treatment group 22·4 (4·5) kg/m2; placebo group 22·4 (4·4) kg/m2.
Mutation class:
Phe508del/Phe508del: treatment group 31 (50%); placebo group 26 (48%).
Phe508del/class 1-6: treatment group 23 (37%); placebo group 22 (41%).
Not Phe508del/class 1: treatment group 3 (5%); placebo group 1 (2%).
Heterozygous/homozygous class 3 - 6: treatment group 2 (3%); placebo group 2 (4%).
Phe508del/unknown class: treatment group 3 (5%); placebo group 3 (6%)
Interventions Treatment: 5 mL pGM169/GL67A (each dose contained 13·3 mg of plasmid DNA and
75 mg of the GL67A lipid mixture)
Placebo: 5 mL placebo (0.9% saline).
Treatment and placebo both nebulised to lungs through a Trudell AeroEclipse II device
(Trudell Medical International, London, ON, Canada)
12 doses at 28 day intervals (plus or minus 5 days) for 12 months
Routine treatments were continued throughout the trial, except for DNase, which was
withheld for 24 hours before and after dosing
Outcomes Primary outcome measure: relative change in % predicted FEV1.
Secondary outcome measures: additional measures of lung function; CT scan scores;
CFQ-R scores; exercise testing; activitymonitoring; sputum inflammatorymarkers; nasal
or bronchial vector specific DNA or mRNA; electrophysiological assessment of CFTR
function; adverse events
Notes Sample size calculation undertaken. A total sample size of 120 assessable participants
calculated to provide 90% power to detect a 6% difference between groups in the mean
change from baseline at a two-sided 5% significance level
Only the primary end point, relative change from baseline to end of treatment in FEV1
% predicted, was reported as ITT.
Risk of bias
Bias Authors’ judgement Support for judgement
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Alton 2015 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was performed, following a
successful screening visit, via the on-line In-
Form database system (Oracle Health Sci-
ences, Reading, UK). All data required for
randomisation and stratification were en-
tered by a member of the study teamwhich
led to the generation of a unique patient
number, corresponding to a blinded, ran-
domised arm of the study. In the event
of computer system failure, a prearranged
manual randomisation method was avail-
able from the InForm team
Allocation concealment (selection bias) Low risk Participants and investigators were masked
to treatment allocation, with the randomi-
sation code known only by pharmacy staff
at the two dosing sites. The unique pa-
tient number was entered onto the partici-
pant’s prescription sheet and submitted to
the study pharmacists who had access to the
unblinding code and prepared the active or
placebo treatment as appropriate
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk 5 ml volumes of pGM169 (13·25 mg)/
GL67A (75 mg) or placebo (saline) were
placed in AeroEclipse II breath-actuated
nebulisers (Trudell Medical Instruments,
London, ON, Canada). To avoid unblind-
ing, nebulisers were taped and a tamper-
proof seal was attached. Study medicines
were prepared by unblinded trial phar-
macists. Clinical study staff, participants
and analysts were blind to allocation until
database lock. 10 ml volumes were placed
in opaque nasal spray devices (GSK parts
No. AR5989 30 ml bottle/AR9488 30 ml
actuator) and the device was primed. De-
tails of consistency and taste of active trial
drug versus placebo have not been provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A total of 24 randomised participants with-
drew from the study. Reasons given for all
of these:
1. Discontinuation prior to initial dose (n
= 4)
Treatment group: 2 reconsidered participa-
tion/withdrew consent
Placebo group: 1 reconsidered participa-
tion/withdrew consent and 1 was clinically
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Alton 2015 (Continued)
unstable
2. Discontinuation after initial dose after
enrolment in ITT population (n = 20)
Treatment group (n = 14): 5 due to time
commitments, 1 wished to discontinue
contraception, 1 changed mind regarding
participation, 1 had borderline FEV1 at
screening and throughout study, 1 lived in
nomadic community and not available for
follow up, 1 had a new culture of MRSA,
1 had a new culture of Mycobacterium ab-
scessus, 1 had a new culture of Burkholderia
cepacia and 2 commenced ivacaftor.
Placebo group (n = 6): 2 due to time com-
mitments, 1 disliked venepuncture, 1 had
increased respiratory adverse events, 1 had a
new culture ofMycobacterium abscessus and
1 commenced ivacaftor.
Selective reporting (reporting bias) Low risk Renal function and anti-nuclear antibod-
ies (as a marker of immune response) were
stated in the protocol but not reported in
the paper
Other bias Low risk Similar baseline characteristics.
Moss 2004
Methods Double-blind placebo-controlled RCT.
Parallel design.
Duration: 3 times (30 day interval).
Multicentre (8 CF centres) in the USA.
Participants 37 participants (15 male, 22 female).
Treatment group n = 20 (6 male, 14 female), placebo group n = 17 (9 male, 8 female).
Mean age 23.7 years. Mean (SD) age: in treatment group 24.2 (8.7) years; in placebo
group 23.2(11.1) years.
Confirmed CF, FEV1 > 60%. Mean (SD) FEV1: in treatment group 82.2 (19.3) and in
placebo group 84.4 (15.1),P = 0.70
Genotype:
F508 homozygous: treatment group 5 (25%), placebo group 13 (77%)
F508 heterozygous: treatment group 12 (60%), placebo group 2 (12%)
Other/unknown: treatment group 3 (15%), placebo group 2 (12%)
Interventions Treatment: 1x10(13) particles tgAAVCF 3 times (30 day interval) nebulised to lungs
Control: matching placebo 3 times (30 day interval) nebulised to lungs
Outcomes Respiratory exacerbations, adverse events, lung function, inpatient episodes, acquisition
of new pathogens, gene expression, change in CT score
24Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Moss 2004 (Continued)
Notes Analysed on intention-to-treat basis.
Additional data requested from author, original data provided
Power calculation undertaken - paper states “Enrollment of 18 subjects per treatment
group provided adequate power to test differences between treatment groups with respect
to the primary and secondary protocol end points”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no further
details given.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, no further details.
Incomplete outcome data (attrition bias)
All outcomes
High risk Analysed on intention-to-treat basis.
42 participants randomised, 37 received at
least one dose of study drug, 35 completed
all 3 doses.
Not clear if withdrawals in placebo or ac-
tive group, data pooled for 37 participants
receiving at least 1 dose. Only 35 partic-
ipants underwent HRCT lung scans, and
just 10 had vector-specific CFTR gene ex-
pression assessed
The first participant, who had received 1
dose of study medication, was withdrawn
from the study as a result of a FDA hold
on the research. The second participant
was withdrawn prior to dosing, then later
was re-screened and was re-randomized,
but withdrew consent prior to dosing. 3
other participants withdrew consent after
randomization but prior to starting treat-
ment because of heavy work schedule, con-
cern about potential risks, and a change of
mind, respectively
Selective reporting (reporting bias) Unclear risk Unclear.
Other bias High risk The placebo group had significantly more
1F508 homozygous participants (77%)
than the CFTR gene replacement group
(25%) (P = 0.01)
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Moss 2007
Methods Double-blind placebo-controlled RCT.
Parallel design.
Duration: 2 times (30-day interval).
Multicentre (12 centres) in USA.
Participants 122 people screened, 109 randomised and 102 participants (54male, 48 female) received
treatment. 98 completed study and 4 stopped early (reasons given - see below)
Treatment group n = 51 (26 male), placebo group n = 51 (28 male).
Mean age 22.6 years, all aged over 12 years. Mean (SD) age: treatment group 23.9 (10.
9) years, placebo group 21.3 (8.7) years.
Confirmed CF, FEV1 > 60% predicted. Mean (SD) FEV1 % predicted: treatment group
84.7 (13.7), placebo group 87.9 (15.5)
Genotype:
AF508 homozygous: treatment group 27 (53%), placebo group 27 (53%)
AF508 heterozygous: treatment group 18 (35%), placebo group 20 (39%)
Interventions Treatment: 1x10(13) particles tgAAVCF 2 times (30 day interval) nebulised to lungs
Control: matching placebo 2 times (30 day interval) nebulised to lungs
Outcomes Respiratory exacerbations, adverse events, lung function.
Notes Analysed on intention-to-treat basis.
Additional data requested from author, original data provided
Sample size calculation based on the initial phase 2 multidose aerosol study. “Enrollment
of 100 subjects, 50 in each treatment arm, would provide 93% power to detect a 0.14 L
difference in the 30-day change in FEV1 between treatment groups, assuming a standard
deviation of the change of 0.20 L in each group. This sample size would also provide
adequate power for detecting 0.3 log10-ng/ml differences between treatment groups in
IL-8.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no further
details given.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, no further details.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat basis. 109 participants
randomised, of whom 102 received at least
1 dose of study drug, 98 completed trial
- 4 participants stopped early. Of these, 1
was in the tgAAVCF treatment group and
3were in the placebo group. The reason the
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Moss 2007 (Continued)
participant from the tgAAVCF group dis-
continued was loss to follow-up. Reasons
for discontinuation in the 3 placebo recipi-
ents included experiencing an adverse event
(unlikely to be related pulmonary exacer-
bation), death (unrelated motorcycle acci-
dent), and other (no response to day 210
phone call)
Selective reporting (reporting bias) High risk Some relevant secondary endpoints, such
as number of days of oral antibiotic use,
remain unreported
Other bias Unclear risk Unclear.
CF: cystic fibrosis
CFTR: cystic fibrosis transmembrane conductance regulator
CT: computerised tomogram scan (of chest)
DNA: deoxyribonucleic acid
DNase: dornase alfa
FEV1: forced expiratory volume in one second
ITT: intention-to-treat
MRSA: methicillin-resistant Staphylococcus aureus
RCT: randomised controlled trial
SD: standard deviation
tgAAVCF: Targeted Genetics Corporation adeno-associated virus encoding CFTR
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Davies 2011 Not a RCT.
Flotte 1996 Not a RCT.
Gill 1997 Applied to nose not to lungs.
Harvey 1999 Not a RCT.
Hyde 2000 Applied to nose not to lungs.
Joseph 2001 Not a RCT.
Knowles 1995 Applied to nose not to lungs.
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(Continued)
Noone 2000 Not a RCT.
Porteous 1997 Applied to nose not to lungs.
Wagner 1999 Applied to sinuses not lungs.
Wagner 2002 Applied to sinuses not lungs.
Zabner 1996 Not a RCT.
Zabner 1997 Not a RCT.
Zuckerman 1999 Not a RCT.
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. CFTR gene replacement therapy versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Respiratory exacerbations
(episodes)
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 5 - 6 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 6 - 9 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Respiratory exacerbations
(number of participants)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 9 - 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Change in FEV1 (L) from
baseline
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 At <24 hours 1 16 Mean Difference (IV, Fixed, 95% CI) -1.40 [-3.07, 0.27]
3.2 At up to 30 days 2 139 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.00, 0.13]
3.3 At up to 2 months 2 138 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.12, 0.02]
4 Change in FEV1 % predicted
from baseline
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 At up to 30 days 2 139 Mean Difference (IV, Fixed, 95% CI) 1.48 [-0.43, 3.39]
4.2 At up to 2 months 2 138 Mean Difference (IV, Fixed, 95% CI) -2.03 [-4.21, 0.14]
4.3 At up to 3 months 1 37 Mean Difference (IV, Fixed, 95% CI) 1.25 [-3.84, 6.34]
5 Change in FVC (L) 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 At <24 hours 1 16 Mean Difference (IV, Fixed, 95% CI) -1.70 [-3.27, -0.13]
5.2 At up to 30 days 2 139 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.05, 0.09]
5.3 At up to 2 months 2 138 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.13, 0.02]
6 Change in FVC (% predicted)
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At up to 30 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 At up to 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 At up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 At up to 4 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.5 At up to 5 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.6 At up to 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.7 At up to 7 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.8 At up to 8 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.9 At up to 9 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.10 At up to 10 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.11 At up to 11 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.12 At up to 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Relative change in FEV1 %
predicted from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 At up to 30 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 At up to 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 At up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 At up to 4 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.5 At up to 5 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.6 At up to 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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7.7 At up to 7 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.8 At up to 8 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.9 At up to 9 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.10 At up to 10 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.11 At up to 11 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.12 At up to 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Number of inpatient episodes 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 Within 5 - 6 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Mild airway symptoms
(Alton-pooled: Cough, wheeze,
tight chest)
1 16 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.57, 1.76]
9.2 Rhinitis 2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.67, 1.14]
9.3 Pharyngitis 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.76, 1.70]
9.4 Headache 2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.51, 1.45]
9.5 Sinusitis 2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.53, 1.54]
9.6 Moderate: Influenza type
symptoms (Alton: pooled)
2 132 Risk Ratio (M-H, Fixed, 95% CI) 3.83 [0.96, 15.33]
9.7 Abdominal pain 2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.36, 1.20]
9.8 Asthma 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [0.48, 7.91]
9.9 Chest pain 2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.50, 1.57]
9.10 Cough 1 37 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.33, 108.56]
9.11 Increased cough 2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.71, 1.10]
9.12 Dyspnoea 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.38, 2.84]
9.13 Fatigue 1 37 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.44, 2.12]
9.14 Fever 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.79, 2.36]
9.15 Decreased lung function 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.63, 2.18]
9.16 Increased Sputum 2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.61, 1.20]
9.17 Severe (Alton: pooled) 1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.18 CF lung exacerbation 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.75, 2.61]
9.19 Hemoptysis 2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.32, 2.47]
9.20 Lung disorder 1 37 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.43, 3.78]
9.21 Lower airway symptoms 1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.89, 4.47]
10 Lower airway potential
difference change from baseline
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 At up to 30 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 At up to 13 months Corr
0.1
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 At up to 13 months Corr
0.5
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 At up to 13 months Corr
0.9
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Lower airway potential
difference change from baseline
(amiloride and low chloride)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 Response to perfusion
with amiloride
1 16 Mean Difference (IV, Fixed, 95% CI) 3.90 [-9.76, 17.56]
11.2 Response to perfusion
with zero chloride solution
1 16 Mean Difference (IV, Fixed, 95% CI) 6.86 [3.77, 9.95]
12 Lower airway potential
difference - post treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 At up to 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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13 Measurement of CFTR protein
expression (SPQ chloride
efflux)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14 Change in validated
computerised tomogram (CT)
score
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 1 Respiratory
exacerbations (episodes).
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 1 Respiratory exacerbations (episodes)
Study or subgroup CFTR gene therapy Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 - 6 months
Moss 2004 6/20 3/17 1.70 [ 0.50, 5.79 ]
2 6 - 9 months
Moss 2007 12/51 9/51 1.33 [ 0.62, 2.89 ]
0.2 0.5 1 2 5
Favours CFTR gene Favours placebo
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Analysis 1.2. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 2 Respiratory
exacerbations (number of participants).
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 2 Respiratory exacerbations (number of participants)
Study or subgroup CFTR gene therapy Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 9 - 12 months
Alton 2015 30/59 26/54 1.06 [ 0.73, 1.53 ]
0.5 0.7 1 1.5 2
Favours CFTR gene therapy Favours placebo
Analysis 1.3. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 3 Change in FEV1
(L) from baseline.
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 3 Change in FEV1 (L) from baseline
Study or subgroup CFTR gene therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At <24 hours
Alton 1999 8 -16.7 (1.7) 8 -15.3 (1.7) 100.0 % -1.40 [ -3.07, 0.27 ]
Subtotal (95% CI) 8 8 100.0 % -1.40 [ -3.07, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
2 At up to 30 days
Moss 2004 20 0.1 (0.2) 17 -0.04 (0.18) 30.0 % 0.14 [ 0.02, 0.26 ]
Moss 2007 51 0 (0.23) 51 -0.03 (0.18) 70.0 % 0.03 [ -0.05, 0.11 ]
Subtotal (95% CI) 71 68 100.0 % 0.06 [ 0.00, 0.13 ]
Heterogeneity: Chi2 = 2.17, df = 1 (P = 0.14); I2 =54%
-2 -1 0 1 2
Favours placebo Favours CFTR gene
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Study or subgroup CFTR gene therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 1.84 (P = 0.066)
3 At up to 2 months
Moss 2004 19 0.02 (0.27) 17 -0.03 (0.24) 17.9 % 0.05 [ -0.12, 0.22 ]
Moss 2007 51 -0.03 (0.21) 51 0.04 (0.19) 82.1 % -0.07 [ -0.15, 0.01 ]
Subtotal (95% CI) 70 68 100.0 % -0.05 [ -0.12, 0.02 ]
Heterogeneity: Chi2 = 1.64, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 7.80, df = 2 (P = 0.02), I2 =74%
-2 -1 0 1 2
Favours placebo Favours CFTR gene
Analysis 1.4. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 4 Change in FEV1 %
predicted from baseline.
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 4 Change in FEV1 % predicted from baseline
Study or subgroup CFTR gene therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At up to 30 days
Moss 2004 20 2.26 (5.92) 17 -0.73 (4.73) 31.0 % 2.99 [ -0.44, 6.42 ]
Moss 2007 51 -0.42 (6.37) 51 -1.22 (5.46) 69.0 % 0.80 [ -1.50, 3.10 ]
Subtotal (95% CI) 71 68 100.0 % 1.48 [ -0.43, 3.39 ]
Heterogeneity: Chi2 = 1.08, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 1.52 (P = 0.13)
2 At up to 2 months
Moss 2004 19 0.07 (7.48) 17 -0.32 (6.92) 21.3 % 0.39 [ -4.31, 5.09 ]
Moss 2007 51 -1.82 (7.11) 51 0.87 (5.39) 78.7 % -2.69 [ -5.14, -0.24 ]
-4 -2 0 2 4
Favours placebo Favours CFTR gene
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Study or subgroup CFTR gene therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 70 68 100.0 % -2.03 [ -4.21, 0.14 ]
Heterogeneity: Chi2 = 1.30, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 1.83 (P = 0.067)
3 At up to 3 months
Moss 2004 20 -1.28 (8.3) 17 -2.53 (7.5) 100.0 % 1.25 [ -3.84, 6.34 ]
Subtotal (95% CI) 20 17 100.0 % 1.25 [ -3.84, 6.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 5.89, df = 2 (P = 0.05), I2 =66%
-4 -2 0 2 4
Favours placebo Favours CFTR gene
Analysis 1.5. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 5 Change in FVC (L).
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 5 Change in FVC (L)
Study or subgroup CFTR gene therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At <24 hours
Alton 1999 8 -16.6 (1.98) 8 -14.9 (1.1) 100.0 % -1.70 [ -3.27, -0.13 ]
Subtotal (95% CI) 8 8 100.0 % -1.70 [ -3.27, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
2 At up to 30 days
Moss 2004 20 0.06 (0.2) 17 -0.07 (0.25) 23.4 % 0.13 [ -0.02, 0.28 ]
Moss 2007 51 0 (0.2) 51 0.01 (0.22) 76.6 % -0.01 [ -0.09, 0.07 ]
Subtotal (95% CI) 71 68 100.0 % 0.02 [ -0.05, 0.09 ]
Heterogeneity: Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
-2 -1 0 1 2
Favours placebo Favours CFTR gene
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Study or subgroup CFTR gene therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 0.62 (P = 0.53)
3 At up to 2 months
Moss 2004 19 0.01 (0.28) 17 -0.01 (0.28) 15.3 % 0.02 [ -0.16, 0.20 ]
Moss 2007 51 -0.01 (0.19) 51 0.06 (0.21) 84.7 % -0.07 [ -0.15, 0.01 ]
Subtotal (95% CI) 70 68 100.0 % -0.06 [ -0.13, 0.02 ]
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi2 = 6.76, df = 2 (P = 0.03), I2 =70%
-2 -1 0 1 2
Favours placebo Favours CFTR gene
Analysis 1.6. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 6 Change in FVC (%
predicted) from baseline.
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 6 Change in FVC (% predicted) from baseline
Study or subgroup CFTR gene therapy Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At up to 30 days
Alton 2015 62 0.82 (6.86) 52 -0.74 (6.87) 1.56 [ -0.97, 4.09 ]
2 At up to 2 months
Alton 2015 60 0.79 (6.92) 52 -1.91 (6.93) 2.70 [ 0.13, 5.27 ]
3 At up to 3 months
Alton 2015 59 1.01 (7.07) 53 -2.95 (7.08) 3.96 [ 1.34, 6.58 ]
4 At up to 4 months
Alton 2015 61 0.37 (7.26) 51 -1.09 (7.28) 1.46 [ -1.24, 4.16 ]
5 At up to 5 months
-4 -2 0 2 4
Favours CFTR gene therapy Favours placebo
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Study or subgroup CFTR gene therapy Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alton 2015 56 0.84 (8.42) 51 -0.31 (8.43) 1.15 [ -2.05, 4.35 ]
6 At up to 6 months
Alton 2015 57 -0.73 (8.71) 49 -0.74 (8.73) 0.01 [ -3.32, 3.34 ]
7 At up to 7 months
Alton 2015 55 1.52 (7.78) 53 -1.04 (7.78) 2.56 [ -0.38, 5.50 ]
8 At up to 8 months
Alton 2015 55 1.99 (8.17) 48 -1.17 (8.18) 3.16 [ 0.00, 6.32 ]
9 At up to 9 months
Alton 2015 59 0.41 (8.26) 51 -0.61 (8.28) 1.02 [ -2.08, 4.12 ]
10 At up to 10 months
Alton 2015 59 0.7 (7.7) 49 -0.28 (7.71) 0.98 [ -1.94, 3.90 ]
11 At up to 11 months
Alton 2015 58 0.86 (6.82) 52 -2.32 (6.83) 3.18 [ 0.63, 5.73 ]
12 At up to 12 months
Alton 2015 60 0.5 (7.3) 54 -2.53 (7.3) 3.03 [ 0.35, 5.71 ]
-4 -2 0 2 4
Favours CFTR gene therapy Favours placebo
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Analysis 1.7. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 7 Relative change in
FEV1 % predicted from baseline.
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 7 Relative change in FEV1 % predicted from baseline
Study or subgroup CFTR gene therapy Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At up to 30 days
Alton 2015 62 0.92 (8.73) 53 -1.66 (8.74) 2.58 [ -0.62, 5.78 ]
2 At up to 2 months
Alton 2015 60 0.42 (7.83) 52 -2.63 (7.85) 3.05 [ 0.14, 5.96 ]
3 At up to 3 months
Alton 2015 59 0.61 (8.5) 53 -2.8 (8.51) 3.41 [ 0.26, 6.56 ]
4 At up to 4 months
Alton 2015 61 -0.39 (8.69) 51 -1.45 (8.72) 1.06 [ -2.18, 4.30 ]
5 At up to 5 months
Alton 2015 56 0.38 (8.59) 51 0.05 (8.6) 0.33 [ -2.93, 3.59 ]
6 At up to 6 months
Alton 2015 58 -0.57 (10.81) 49 -1.42 (10.82) 0.85 [ -3.26, 4.96 ]
7 At up to 7 months
Alton 2015 56 1.56 (10.26) 53 -2.14 (10.26) 3.70 [ -0.15, 7.55 ]
8 At up to 8 months
Alton 2015 55 1.09 (10.14) 48 -1.16 (10.15) 2.25 [ -1.68, 6.18 ]
9 At up to 9 months
Alton 2015 59 -1.54 (9.69) 51 -1.63 (9.71) 0.09 [ -3.55, 3.73 ]
10 At up to 10 months
Alton 2015 59 -0.29 (11.39) 49 -1.65 (11.42) 1.36 [ -2.96, 5.68 ]
11 At up to 11 months
Alton 2015 58 -0.02 (9.32) 52 -3.32 (9.33) 3.30 [ -0.19, 6.79 ]
12 At up to 12 months
Alton 2015 60 -0.35 (9.54) 54 -4.01 (9.55) 3.66 [ 0.15, 7.17 ]
-10 -5 0 5 10
Favours placebo Favours CFTR gene therapy
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Analysis 1.8. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 8 Number of
inpatient episodes.
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 8 Number of inpatient episodes
Study or subgroup CFTR gene therapy Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Within 5 - 6 months
Moss 2004 7/20 7/17 0.85 [ 0.37, 1.94 ]
0.2 0.5 1 2 5
Favours CFTR gene Favours placebo
Analysis 1.9. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 9 Adverse events.
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 9 Adverse events
Study or subgroup CFTR gene therapy Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mild airway symptoms (Alton-pooled: Cough, wheeze, tight chest)
Alton 1999 6/8 6/8 100.0 % 1.00 [ 0.57, 1.76 ]
Subtotal (95% CI) 8 8 100.0 % 1.00 [ 0.57, 1.76 ]
Total events: 6 (CFTR gene therapy), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Rhinitis
Moss 2004 11/20 10/17 23.6 % 0.94 [ 0.53, 1.64 ]
Moss 2007 30/51 35/51 76.4 % 0.86 [ 0.64, 1.15 ]
Subtotal (95% CI) 71 68 100.0 % 0.88 [ 0.67, 1.14 ]
Total events: 41 (CFTR gene therapy), 45 (Placebo)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
0.01 0.1 1 10 100
Favours CFTR gene Favours placebo
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Study or subgroup CFTR gene therapy Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.00 (P = 0.32)
3 Pharyngitis
Moss 2004 9/20 7/17 28.5 % 1.09 [ 0.52, 2.31 ]
Moss 2007 22/51 19/51 71.5 % 1.16 [ 0.72, 1.86 ]
Subtotal (95% CI) 71 68 100.0 % 1.14 [ 0.76, 1.70 ]
Total events: 31 (CFTR gene therapy), 26 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
4 Headache
Moss 2004 7/20 6/17 30.2 % 0.99 [ 0.41, 2.39 ]
Moss 2007 12/51 15/51 69.8 % 0.80 [ 0.42, 1.54 ]
Subtotal (95% CI) 71 68 100.0 % 0.86 [ 0.51, 1.45 ]
Total events: 19 (CFTR gene therapy), 21 (Placebo)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
5 Sinusitis
Moss 2004 7/20 5/17 26.5 % 1.19 [ 0.46, 3.07 ]
Moss 2007 12/51 15/51 73.5 % 0.80 [ 0.42, 1.54 ]
Subtotal (95% CI) 71 68 100.0 % 0.90 [ 0.53, 1.54 ]
Total events: 19 (CFTR gene therapy), 20 (Placebo)
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
6 Moderate: Influenza type symptoms (Alton: pooled)
Alton 1999 7/8 1/8 48.3 % 7.00 [ 1.10, 44.61 ]
Alton 2015 1/62 1/54 51.7 % 0.87 [ 0.06, 13.59 ]
Subtotal (95% CI) 70 62 100.0 % 3.83 [ 0.96, 15.33 ]
Total events: 8 (CFTR gene therapy), 2 (Placebo)
Heterogeneity: Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.90 (P = 0.057)
7 Abdominal pain
Moss 2004 6/20 6/17 31.7 % 0.85 [ 0.34, 2.15 ]
Moss 2007 8/51 14/51 68.3 % 0.57 [ 0.26, 1.24 ]
Subtotal (95% CI) 71 68 100.0 % 0.66 [ 0.36, 1.20 ]
Total events: 14 (CFTR gene therapy), 20 (Placebo)
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
8 Asthma
Moss 2004 4/20 2/17 81.2 % 1.70 [ 0.35, 8.17 ]
Moss 2007 1/51 0/51 18.8 % 3.00 [ 0.13, 71.96 ]
Subtotal (95% CI) 71 68 100.0 % 1.94 [ 0.48, 7.91 ]
0.01 0.1 1 10 100
Favours CFTR gene Favours placebo
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Study or subgroup CFTR gene therapy Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 5 (CFTR gene therapy), 2 (Placebo)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
9 Chest pain
Moss 2004 6/20 7/17 40.8 % 0.73 [ 0.30, 1.75 ]
Moss 2007 11/51 11/51 59.2 % 1.00 [ 0.48, 2.10 ]
Subtotal (95% CI) 71 68 100.0 % 0.89 [ 0.50, 1.57 ]
Total events: 17 (CFTR gene therapy), 18 (Placebo)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.69)
10 Cough
Moss 2004 3/20 0/17 100.0 % 6.00 [ 0.33, 108.56 ]
Subtotal (95% CI) 20 17 100.0 % 6.00 [ 0.33, 108.56 ]
Total events: 3 (CFTR gene therapy), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
11 Increased cough
Moss 2004 12/20 12/17 25.5 % 0.85 [ 0.53, 1.36 ]
Moss 2007 34/51 38/51 74.5 % 0.89 [ 0.70, 1.15 ]
Subtotal (95% CI) 71 68 100.0 % 0.88 [ 0.71, 1.10 ]
Total events: 46 (CFTR gene therapy), 50 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
12 Dyspnoea
Moss 2004 6/20 4/17 74.2 % 1.28 [ 0.43, 3.78 ]
Moss 2007 0/51 1/51 25.8 % 0.33 [ 0.01, 8.00 ]
Subtotal (95% CI) 71 68 100.0 % 1.03 [ 0.38, 2.84 ]
Total events: 6 (CFTR gene therapy), 5 (Placebo)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
13 Fatigue
Moss 2004 8/20 7/17 100.0 % 0.97 [ 0.44, 2.12 ]
Subtotal (95% CI) 20 17 100.0 % 0.97 [ 0.44, 2.12 ]
Total events: 8 (CFTR gene therapy), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
14 Fever
Moss 2004 8/20 8/17 55.3 % 0.85 [ 0.41, 1.78 ]
Moss 2007 14/51 7/51 44.7 % 2.00 [ 0.88, 4.54 ]
0.01 0.1 1 10 100
Favours CFTR gene Favours placebo
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Study or subgroup CFTR gene therapy Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 71 68 100.0 % 1.36 [ 0.79, 2.36 ]
Total events: 22 (CFTR gene therapy), 15 (Placebo)
Heterogeneity: Chi2 = 2.42, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.11 (P = 0.27)
15 Decreased lung function
Moss 2004 3/20 4/17 30.2 % 0.64 [ 0.17, 2.46 ]
Moss 2007 14/51 10/51 69.8 % 1.40 [ 0.69, 2.86 ]
Subtotal (95% CI) 71 68 100.0 % 1.17 [ 0.63, 2.18 ]
Total events: 17 (CFTR gene therapy), 14 (Placebo)
Heterogeneity: Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.49 (P = 0.62)
16 Increased Sputum
Moss 2004 13/20 12/17 36.1 % 0.92 [ 0.59, 1.44 ]
Moss 2007 19/51 23/51 63.9 % 0.83 [ 0.52, 1.32 ]
Subtotal (95% CI) 71 68 100.0 % 0.86 [ 0.61, 1.20 ]
Total events: 32 (CFTR gene therapy), 35 (Placebo)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
17 Severe (Alton: pooled)
Alton 1999 0/8 0/8 Not estimable
Subtotal (95% CI) 8 8 Not estimable
Total events: 0 (CFTR gene therapy), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
18 CF lung exacerbation
Moss 2004 6/20 3/17 24.5 % 1.70 [ 0.50, 5.79 ]
Moss 2007 13/51 10/51 75.5 % 1.30 [ 0.63, 2.69 ]
Subtotal (95% CI) 71 68 100.0 % 1.40 [ 0.75, 2.61 ]
Total events: 19 (CFTR gene therapy), 13 (Placebo)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
19 Hemoptysis
Moss 2004 5/20 4/17 68.4 % 1.06 [ 0.34, 3.34 ]
Moss 2007 1/51 2/51 31.6 % 0.50 [ 0.05, 5.34 ]
Subtotal (95% CI) 71 68 100.0 % 0.88 [ 0.32, 2.47 ]
Total events: 6 (CFTR gene therapy), 6 (Placebo)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
0.01 0.1 1 10 100
Favours CFTR gene Favours placebo
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Study or subgroup CFTR gene therapy Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
20 Lung disorder
Moss 2004 6/20 4/17 100.0 % 1.28 [ 0.43, 3.78 ]
Subtotal (95% CI) 20 17 100.0 % 1.28 [ 0.43, 3.78 ]
Total events: 6 (CFTR gene therapy), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
21 Lower airway symptoms
Alton 2015 16/62 7/54 100.0 % 1.99 [ 0.89, 4.47 ]
Subtotal (95% CI) 62 54 100.0 % 1.99 [ 0.89, 4.47 ]
Total events: 16 (CFTR gene therapy), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
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Analysis 1.10. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 10 Lower airway
potential difference change from baseline.
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 10 Lower airway potential difference change from baseline
Study or subgroup CFTR gene therapy Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At up to 30 days
Alton 1999 8 -0.81 (9.02) 8 2.53 (6.48) -3.34 [ -11.04, 4.36 ]
2 At up to 13 months Corr 0.1
Alton 2015 10 1.8 (7.21) 7 2.1 (6.24) -0.30 [ -6.73, 6.13 ]
3 At up to 13 months Corr 0.5
Alton 2015 10 1.8 (5.38) 7 2.1 (4.86) -0.30 [ -5.21, 4.61 ]
4 At up to 13 months Corr 0.9
Alton 2015 10 1.8 (2.4) 7 2.1 (2.88) -0.30 [ -2.90, 2.30 ]
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Analysis 1.11. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 11 Lower airway
potential difference change from baseline (amiloride and low chloride).
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 11 Lower airway potential difference change from baseline (amiloride and low chloride)
Study or subgroup CFTR gene therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Response to perfusion with amiloride
Alton 1999 8 -12.6 (14.66) 8 -16.5 (13.17) 100.0 % 3.90 [ -9.76, 17.56 ]
Subtotal (95% CI) 8 8 100.0 % 3.90 [ -9.76, 17.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 Response to perfusion with zero chloride solution
Alton 1999 8 5.4 (3.82) 8 -1.46 (2.29) 100.0 % 6.86 [ 3.77, 9.95 ]
Subtotal (95% CI) 8 8 100.0 % 6.86 [ 3.77, 9.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.36 (P = 0.000013)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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Analysis 1.12. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 12 Lower airway
potential difference - post treatment.
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 12 Lower airway potential difference - post treatment
Study or subgroup CFTR gene therapy Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At up to 12 months
Alton 2015 10 -14 (5.38) 7 -15.7 (5.38) 1.70 [ -3.50, 6.90 ]
-10 -5 0 5 10
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Analysis 1.13. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 13 Measurement
of CFTR protein expression (SPQ chloride efflux).
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 13 Measurement of CFTR protein expression (SPQ chloride efflux)
Study or subgroup CFTR gene therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alton 1999 6 0.4 (0.49) 7 0.1 (0.22) 0.30 [ -0.12, 0.72 ]
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 CFTR gene replacement therapy versus placebo, Outcome 14 Change in
validated computerised tomogram (CT) score.
Review: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Comparison: 1 CFTR gene replacement therapy versus placebo
Outcome: 14 Change in validated computerised tomogram (CT) score
Study or subgroup CFTR gene therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Moss 2004 18 -1 (3) 17 0 (6) -1.00 [ -4.17, 2.17 ]
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours CFTR gene Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Primary outcomes measured
Study name Respiratory exacerbations Lung function Days in hospital Survival
Alton 1999 Not measured. Measured, but only at 6
hours post-dose to monitor
for adverse effects.
Reported in this review.
Not measured. Not measured.
Alton 2015 Measured respiratory exac-
erbations requiring any an-
tibiotics (IV or oral) be-
tween 11 - 12 months
Reported in this review.
Measured relative change in
FEV1 % predicted, change
in FVC % predicted, at
baseline, 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11 and 12 months,
Measured KCOc, TLCOc,
lung clearance index and
MEF25−75% at 12 months.
1, 2, 3 and 12 month data
reported in this review.
Not measured. Not measured.
Moss 2004 Measured respiratory exac-
erbations requiring IV an-
tibiotics within 150 days.
Measured FEV1, FEV1 %
predicted, FVC, at baseline,
30, 60, 90 and 150 days.
Not measured,
although number of inpa-
tient episodes within 150
days measured.
Not measured.
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Table 1. Primary outcomes measured (Continued)
Reported in this review. Day 30 and 60 data re-
ported in this review. Reported in this review.
Moss 2007 Measured respiratory exac-
erbations requiring IV an-
tibiotics within 210 days.
Reported in this review.
Measured FEV1, FEV1 %
predicted, FVC, at baseline,
14, 30, 45, 60, 75 and 90
days.
Day 30 and 60 data re-
ported in this review.
Not measured. Not measured.
FEV1: forced expiratory volume in one second
FVC: forced expiratory volume
IV: intravenous
KCOc: diffusion capacity of the alveolar capillary membrane
MEF25−75%: mid-expiratory flow between 25% and 75% of FVC
TLCOc: transfer factor of the lung for carbon monoxide (TLCOc)
Table 2. Secondary outcomes measured
Study
name
Extra
treatment
Adverse
events
Quality of
life
School or
work days
Nutrition New
pathogens
Sputum
rheology
Mucus
clearance
Airway
PD
Alton
1999
Not mea-
sured.
Measured.
Reported
in this re-
view.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
Only mea-
sured sac-
charine
nasal mu-
cocil-
iary clear-
ance, this is
not an ef-
ficacy mea-
sure
for CFTR
gene
replace-
ment ther-
apy to the
lung.
Not
reported.
Mea-
sured base-
line poten-
tial differ-
ence,
response to
perfu-
sion with
amiloride,
and
response to
low chlo-
ride solu-
tion
and isopre-
naline,
measured
at baseline
and 2 days
after study
drug.
Reported
in review.
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Table 2. Secondary outcomes measured (Continued)
Alton
2015
Not mea-
sured.
Mea-
sured to 12
months
Reported
in this re-
view.
Measured
at baseline
and post
treatment
(up to 12
months).
Reported
in this re-
view.
Not mea-
sured
Measured
at baseline
and
post treat-
ment (up
to12
months).
Reported
in this re-
view.
Measured
Pseu-
domonas
aeruginosa,
Staphy-
lococcus
aureus and
Haemophilus
Influenzae
at baseline
and post
treatment
(up to 12
months).
Reported
in this re-
view.
Not mea-
sured.
Mea-
sured base-
line and
post treat-
ment
(up to 12
months)
24 hour
sputum
weight
Reported
in this re-
view.
Mea-
sured base-
line poten-
tial differ-
ence and
response to
zero chlo-
ride solu-
tion
and isopre-
naline
measured
at base-
line and 28
days (+/- 5
days) post
treatment
(up to 12
months)
Reported
in this re-
view.
Moss 2004 Not mea-
sured.
Measured
to 150
days.
Reported
in this re-
view.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
Mea-
sured Pseu-
domonas
aerug-
inosa and
Staphy-
lococcus au-
reus,
(at baseline
and Day
90) but
data are in-
complete.
Reported
in review.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
Moss 2007 Not mea-
sured.
Measured
to 210
days.
Reported
in this re-
view.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
Not mea-
sured.
CFTR: cystic fibrosis transmembrane conductance regulator
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A P P E N D I C E S
Appendix 1. Search strategy: National Institutes for Health (NIH) Genetic modification Clinical
Research Information System (GeMCRIS)
Search dates: 1992 to 20 April 2016
Search term: “cystic fibrosis” (as the medical condition)
WH A T ’ S N E W
Last assessed as up-to-date: 16 June 2016.
Date Event Description
21 July 2016 Amended Order of authors on byline amended.
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 2, 2007
Date Event Description
16 June 2016 New citation required but conclusions have not
changed
Despite the addition of a new study to this updated
review, our conclusions have not changed. Three new
authors have joined the review team. Dr Tim Lee
has stepped down as lead author and Professor Kevin
Southern has taken this role on
16 June 2016 New search has been performed A search of the Cystic Fibrosis & Genetic Disorders
Review Group’s Cystic Fibrosis Trials Register identi-
fied eight additional references to the previously listed
ongoing study which is now included in the review
(Alton 2015).
19 September 2013 New citation required but conclusions have not
changed
While a new study has been identified, it is still ongo-
ing and has not yet been assessed for inclusion in this
review, hence our conclusions remain the same
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(Continued)
19 September 2013 New search has been performed A search of the Cystic Fibrosis & Genetic Disorders
Group’s Cystic Fibrosis Trials Register identified four
references to a single ongoing study which is poten-
tially eligible for inclusion in this review, but will be
assessed in full once completed (Alton 2013a)
29 August 2012 New citation required but conclusions have not
changed
No new studies were included in this update of the
review, so the conclusions remain the same
29 August 2012 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
did not identify any new studies potentially eligible
for inclusion in the review
28 September 2011 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
and an additional search ofGeMCRIS did not identify
any potentially eligible references for this review
A study previously listed as ongoing, has now been
excluded after confirmation from the investigators that
the study did not have a control arm (Alton 2009)
12 August 2010 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
identified one additional reference for possible inclu-
sion in this review (Griesenbach 2008). This abstract
described plans for a future clinical trial and has not
been included
9 September 2009 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
did not identify any potentially eligible references for
inclusion in this review
Through personal communication we have identified
a new ongoing trial (Alton 2009a)
12 August 2009 Amended Contact details updated.
11 November 2008 Amended Converted to new review format.
11 November 2008 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
did not identify any potentially eligible references for
this review
20 February 2008 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
identified one new reference (Moss 2007). This is the
full paper relating to the abstracts previously included
under the study ID Moss 2005. This paper reported
full adverse event follow up that had previously been
reported as “incomplete”, and the new data have been
incorporated into the adverse event analyses in this
update
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(Continued)
20 February 2008 Amended We have replaced the original ’Synopsis’ with a new
’Plain language summary’ in line with latest guidance
from The Cochrane Collaboration
21 February 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
The protocol and review were conceived and drafted by Dr Tim Lee and Professor Kevin Southern. Both authors selected studies and
extracted data.
From the update in 2015, three new authors joined the team: Jahan Penny-Dimri and Luke Perry undertook study selection and data
extraction and Aisha Aslam undertook analyses and drafted the review update.
Professor Southern acts as guarantor for the review.
D E C L A R A T I O N S O F I N T E R E S T
All authors: none known.
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Medical Subject Headings (MeSH)
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Tests; Targeted Gene Repair [adverse effects; ∗methods]
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